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Foreword
The reason for the development of the National Cancer Control Programme 
(Dutch NCCP - Nationaal Programma Kankerbestrijding) was the fact 
that evidence-based guidelines and protocols for diagnosis and treatment  
were not being employed by all practitioners, institutions and care providers  
in the care chain, which encompasses primary care (prevention), treatment and 
aftercare. 
Against that background, the Dutch NCCP started on 4 November 2004 as  
a collaborative venture of five Dutch parties all involved in cancer control from 
different perspectives with the aim of improving cancer control.
The focus was on improvement of coherence, cooperation and chain care between and with all 
professionals, organizations, care institutions, insurers, ministries and patients’ associations involved 
in cancer control. Such a goal had never been achieved before and the Dutch NCCP was considered 
to be a great challenge.
After the implementation of the structure of the Dutch NCCP, the focus moved to the content. This 
meant not only focusing our attention purely on improved techniques in prevention, screening, 
treatment and palliative care, but also considering behavioural and psychosocial aspects playing a 
role. The Dutch NCCP’s objective is to tackle the entire combination of human aspects. Psychosocial 
counselling of patients is after all just as important as clinical technique, as are improved links in the 
chain of care. 
This (holistic) approach appeals to me personally, and it is something I am happy to promote; it is 
also fully supported by the members of the Dutch NCCP.
The results achieved so far reveal that the Dutch NCCP has contributed to a faster, more complete 
and more effective chain of care, including prevention and aftercare. Monitoring of achieved goals 
and the development of future initiatives will need to continue and we will keep discussing the best 
way to do this.
The goals which have been achieved are described in the present report.
Ir. Hans de Goeij
Chairman of the Dutch National Cancer Control Programme 2005-2010 
and former Director-General for Public Health of the Ministry of Health, Welfare and Sport (2002-
2009)
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Introduction
This report describes the developments regarding the overall goals of the Dutch NCCP and the 
activities and achievements of the NCCP1 working groups.
Scope of the National Cancer Control Programme (Dutch NCCP) 2005-2010
In November 2004 the first Dutch NCCP vision and summary for 2005-2010 were published (www.
npknet.nl). Both the fact that within 10 years (from 2005 to 2015) the incidence of cancer patients 
will increase from 78,000 to 95,000 and the fact that in the same period the number of people 
suffering from cancer will almost double, will engender a major increase in the demand for care. In 
addition, more than 200 different organizations (besides hospitals) and a tremendous number of 
individuals are involved in cancer control on a daily basis, bringing their own knowledge, insights and 
passion to the job. However, they were not operating within a mutually agreed framework on the 
basis of common priorities or within a comprehensive management structure. Facing the lack of 
sufficient coherence, the risk of less than optimal performance and the major increase in the cancer 
burden, the Association of Comprehensive Cancer Centres (VIKC), the Ministry of Health, Welfare 
and Sport (VWS), the Dutch Cancer Society (KWF Kankerbestrijding; hereafter: KWF), the Dutch 
Federation of Cancer Patients’ Organizations (NFK) and the Dutch Association of Health and Social 
Care Insurance Companies (ZN) took the initiative to set up the first Dutch NCCP. The Dutch NCCP 
was not meant to be a means of obtaining more financial support for cancer control. It was to be an 
initiative that would be neutral in terms of budget and that would realize reallocation on the basis of 
priorities. The programme, which covers all aspects of cancer control (from prevention, screening 
and diagnosis to aftercare, psychosocial care, education and research), ensures coherent priorities 
and measurable objectives. The Dutch NCCP should result in: 
 – the healthiest possible population;
 – less cancer;
 – greater likelihood of surviving the disease;
 – lower death rates
 – optimum quality of life for patients and their family and friends;
 – a manageable and efficient system enabling the best possible cancer care.
Based on the more than 150 broad and extensive targets devised within the various domains of 
comprehensive cancer control, the Dutch NCCP’s Steering Committee selected and prioritized seven 
themes:
 – discouraging smoking;
 – implementation of colorectal cancer screening;
 – improvement of the capacity for translating screening to regular care;
 – improvement in the quality and accessibility of cancer care;
 – psychosocial care;
 – translational research;
 – education in oncology for medical specialists and nurses.
 – In 2006 and 2007, the Steering Committee set up working groups dedicated to these seven 
themes. 
Why a progress report?
The report aims to help policy makers understand past efforts in cancer control enabling them to 
better allocate health resources. It highlights the key successes (and failures) in cancer control by 
showing the results achieved, thus enabling policy makers to better determine the most appropriate 
strategies for cancer control in the Netherlands.
1 A list of acronyms used can be found at the end of this report.
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What’s in this report?
The progress report is divided into different chapters: an overview of cancer control in the 
Netherlands; prevention, screening, quality of care, psychosocial care, education, research and 
conclusions. Each chapter offers an overview of the objectives based on the Dutch NCCP report 
2005-2010 and a description of what has been achieved during this period. 
The data and results used have been obtained from various sources (mentioned under the tables 
and figures) and these sources are responsible for the results used as scientific evidence. All data 
and results used have been checked with the sources concerned.
10
Cancer in the Netherlands
In 2009, cancer became the leading cause of death in the Netherlands. In that year more than 
42,000 people died of cancer. The proportion of all deaths attributable to cancer has increased over 
the last decades from 24% in the early 1970s to 32% at present. In 2010, an estimated number of 
92,500 new cases of cancer will be diagnosed in the Netherlands: 48,000 in males and 44,500 in 
females. Survival has increased: of the patients diagnosed between 2003 and 2007, 59% was still 
alive five years after diagnosis, compared to 47% of the patients diagnosed between 1988 and 1992 
(www.kankerregistratie.nl).
Organization and structure of cancer control in the Netherlands
In the Netherlands, the provision of cancer services is the responsibility of each individual hospital. 
Since the end of the 1970s, nine Comprehensive Cancer Centres (IKCs; network organizations) have 
been supporting professionals in improving the quality of cancer care. Over time, national 
associations of (medical) specialists in oncology (medical oncologists: NVRO; surgical oncologists: 
NVCO, radiotherapists: NVRO, nurses in oncology: NvOV, psychosocial oncologists: NVPO) and 
many national multidisciplinary tumour working groups in oncology were installed in order to develop 
more cohesive plans. Patients in need for help, support or information are able to obtain this 
information via the website or telephone help line of KWF. During the last 10 years the voice of 
patients, through NFK and cancer-specific patients’ associations, have become louder.
11
Interview with Els Borst-Eilers, chair of the Dutch Federation of Cancer 
Patients’ Organizations
“Psychosocial care has progressed in leaps and bounds”
As chair of the Dutch Federation of Cancer Patients’ 
Organizations (NFK), Els Borst has been involved in the 
National Cancer Control Programme (Dutch NCCP) since 
its inception. The former Dutch Minister of Health, Welfare 
and Sport remains a staunch supporter of a 
thorough-going plan to tackle cancer. “This disease is a 
major problem, and major problems require a large-scale 
approach.” 
Els Borst has served as chairperson of the NFK since 1 January 2003. Established in 1991, NFK is 
the umbrella organization for some 25 cancer patient associations. As stated on its website (www.
nfk.nl), “NFK represents the interests of people who either have cancer or have had it in the past. 
Whenever policy on oncological care is discussed, we are there to take part in the proceedings. We 
think and speak from the perspective of cancer patients. The patient organizations that make up the 
NFK represent approx. half a million former and current cancer patients. Around 25,000 of these are 
members of one of the organizations.”
Borst – who served as Minister of Health, Welfare and Sport in the Dutch government from 
August 1994 to May 2002 – has only herself to thank for her current position, she says with a wink. 
“When I approached the end of my tenure as minister, I was of course often asked about my plans 
for the future. On one of those occasions, I replied that I wanted to get involved with patient 
organizations. I believed that the position of patients needed to be enhanced, and that the interests 
of patients could be promoted more effectively.” It came as little surprise, then, that the NFK came 
knocking at my door shortly afterwards”, asking the retired minister how she would feel about taking 
up the key position of chairperson.
This was a proposition that Borst did not have to think about for very long. As NFK chair, she would 
be in a prime position to promote the interests of patients and strengthen their position. Borst also 
had more personal reasons for accepting the offer. “My husband died of cancer, as have a number 
of my personal acquaintances. Therefore, I was well aware of the impact that this disease has on 
patients and their loved ones. In my previous profession as a physician, I have also dealt with 
patients who suffered from cancer.” Borst will vacate her position as chairperson of Dutch NCCP 
shortly. After being reappointed for a second four-year period in 2007, she will reach her maximum 
term at the end of this year and leave NFK.
Borst believes that it was only logical for the NFK to be involved in the National Cancer Control 
Programme from the start. “After all, you cannot make policy without taking the interests of the 
patients into account. ‘No decision-making without patient representation’, we say at the NFK. As 
patients are becoming more assertive and standing up for themselves, the way is paved for patient 
organizations to play a more prominent role.” 
During a conference on smoking cessation organized by the Dutch NCCP and STIVORO (an 
organization that helps people to stop smoking) on 16 June 2010, Borst presented the previous 
Dutch NCCP Monitor to Paul Huijts, Director-General of Public Health at the Ministry of Health, 
Welfare and Sport. The report concluded that most of the targets set in 2006 for combating cancer 
in the Netherlands have not yet been achieved. 
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For example, it emerged that none of the targets for the promotion of a healthier lifestyle have been 
achieved. The incidence of cancer has also risen, predominantly due to the increase in the 
percentage of senior citizens in the Netherlands.
“Nevertheless, we should not lose heart”, Borst insists. “I am a realistic person. You cannot make 
the world a better place in a mere five years. At the same time, you have to dare to set your sights 
high. In a number of areas, we have made considerable progress and there have even been 
indications of positive developments. For instance, responsibilities in the field of oncological care are 
now being divided much more effectively and we have developed clear quality standards which are 
being complied with and monitored. These measures will certainly prove worthwhile. The field of 
psychosocial care has also progressed in leaps and bounds. Just a few years ago, cancer was 
approached almost purely from a treatment point of view, paying little attention to the psychosocial 
aspects. Thankfully this situation has changed, although patients still receive insufficient 
psychosocial support in my opinion. And these are not the only tangible results achieved by the 
National Cancer Control Programme.”
The chairperson of the NFK is well aware that there are many steps yet to be taken. One example 
concerns reducing the number of smokers. “The percentage of smokers was on the decline for 
years, but has now levelled out at twenty-eight percent. This is still far too high, especially 
considering that thirty percent of cancer-related deaths are caused by smoking. In short, there is still 
much to be accomplished in this area. The central issue at the conference was how to improve 
smoking cessation rates in the Netherlands. A number of foreign experts at the conference were 
quite critical of the fact that there are still so many smokers here. In many countries the percentage 
of smokers has declined considerably thanks to a focused, multi-pronged approach. In other words, 
it is possible. We have to devote ourselves more fully to the issue, and that includes addressing the 
pernicious influence of the tobacco industry.”
Borst believes that the National Cancer Control Programme has provided the oncological care sector 
with a new sense of energy and direction. “There is now much more cooperation within the sector 
and all parties are acquainted with one another, which is essential. On the other hand, we have to be 
careful that the organization does not become overly bureaucratic. I am well aware of the necessity 
of setting up working groups and writing reports, but once those reports are finished we have to 
make sure that doctors, nurses and other parties work in the agreed manner. As far as I’m 
concerned, we need to place more emphasis on this and measure progress in this area from now 
on.”
The soon-to-be-former chairperson of the NFK hopes that the National Cancer Control Programme 
will continue beyond 2010. “We should definitely continue with this programme. While many aspects 
of oncological care have been improved, we are still a long way from achieving our aims. There are 
still many steps to be taken. In that sense, I am all for a new five-year programme. Long live Dutch 
NCCP 2!”
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Over the last decade, huge changes in the financing of the health care system have increased the 
responsibilities of health insurance companies and have given them more options to buy care based 
on quality indicators. As a consequence, the development of a free market health system is being 
stimulated for the medical as well as the financial outcomes (competition and benchmarking 
between hospitals). Although the Ministry of Health, Welfare and Sport has been focusing more and 
more on chain care, the above-mentioned changes are considered to be obstacles for the promotion 
and facilitation of collaboration between hospitals, between disciplines within a hospital or between 
hospitals and first-line care.
Recently, several reports on the organization and structure of cancer care have been published, 
including “Zorgketen voor kankerpatienten moet verbeteren” (Care chain for cancer patients must 
improve)1 by the Health Care Inspectorate (IGZ) and “Kwaliteit van kankerzorg in Nederland” (Quality 
of cancer care in the Netherlands)2 by KWF’s Cancer Signalling Committee. The recommendations 
in these reports promote a more comprehensive management structure, a mutual framework for 
optimal collaboration in terms of responsibilities, skills, equipment and transparency. Initiatives on 
transparency by such organizations as the Dutch Health Care Transparency Programme  
(www.zichtbarezorg.nl), the “Regieraad” and the National Institute of Quality in Health, are all aiming 
for harmonization and understanding of the quality process of oncological care.
How does the Netherlands compare to other countries?
Only few European countries had an NCCP at the beginning of the year 2000. Due to promotion by 
and support from the WHO, the UICC and the EU, more and more countries are now aware of their 
cancer burden and are developing their own cancer plan. Comparison between NCCPs of various 
European countries (Eurocanplus+: www.eurocanplus.org) showed that most of them did not cover 
all domains, nor did they formulate the goals in such a way that these could be monitored or 
evaluated; the NCCPs of the UK and the Netherlands were the exceptions3,4. 
Cancer burden: the Netherlands compared to other countries
The cancer incidence in the Netherlands is high compared to other European countries. This applies 
especially to smoking-related cancers in women5. 
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Cancer incidence6 
 – In 2008, 89,228 new cases of cancer were diagnosed in the Netherlands. During the period 
2005-2008 the number of new cancer cases increased by 2.3% per year.
 – The increase in the number of elderly people diagnosed with cancer is the main cause of this 
trend.
 – In the Netherlands, cancer remains mainly a disease affecting elderly people. In 2008, 58% of 
all new cases were diagnosed among persons aged 65 years and older. Less than 1% of all 
cases occurred among persons under the age of 20.
 – The most common types of cancer are breast cancer, colorectal cancer, lung cancer, skin 
cancer (excluding basal cell carcinoma) and prostate cancer. These five types of cancer 
combined account for over two thirds of all new cases of cancer in the Netherlands.
 – In the Netherlands, as in other countries of the world, breast cancer is the type of cancer 
diagnosed most frequently in women; in 2008, breast cancer was diagnosed in 13,005 
women in the Netherlands (95.3 cases per 100,000 females, according to the World 
Standardized Rate (WSR)). Worldwide, an estimated 1.38 million new breast cancer cases 
were diagnosed in 2008 among women (23% of all cancers), and it ranks second overall 
(10.9% of all cancers). Incidence rates are high (more than 80 per 100,000, WSR) in 
developed regions of the world (except Japan) and low (less than 40 per 100,000, WSR) in 
most of the developing regions.
 – The absolute incidence of colorectal cancer in the Netherlands was 12,117 in 2008 (6519 
males and 5598 females): two thirds of these tumours were located in the colon. Like in the 
rest of the world, it was the third most common cancer in men (663,000 cases worldwide, or 
10.0% of the total number) and the second most common cancer in women (570,000 cases, 
or 9.4% of the total number) in 2008. Almost 60% of cases occur in developed regions. 
 – Worldwide, lung cancer has been the most common cancer for several decades, and in 2008 
there were an estimated 1.61 million new cases, representing 12.7% of all new cancers. In 
the Netherlands, lung cancer incidence is still increasing in females: in 2008, 4047 cases 
were diagnosed (27.7 per 100,000 females, WSR), which represents an absolute increase of 
15
43% from 2005 to 2008. In males, lung cancer incidence decreased by 15% from 2005 to 
2008. In 2008, 6729 cases were diagnosed (46.0 per 100,000 males, WSR), making it the 
second most common cancer in males in the Netherlands. Worldwide it is the fourth most 
common cancer in women (513,000 cases, or 8.5% of all cancers in 2008) and still the most 
common cancer in men (1.1 million cases, or 16.5% of the total number). It was also the most 
common cause of death from cancer worldwide, with 1.38 million deaths (18.2% of the total 
number). The majority of cases now occur in developing countries (55%).
 – Skin cancer in general (excluding basal cell carcinoma) increased in the Netherlands to 
10,524 new cancer cases in 2008. During the period between 2005 and 2008, melanoma 
incidence increased by 5% in females to 1437 new cases in 2008 (18.6 per 100,000 females, 
WSR) and by 6% in males to 1026 new cases in 2008 (14.8 per 100,000 males, WSR). 
Worldwide, melanoma has an incidence rate of 2.8 per 100,000, with a total number of new 
cases in 2008 of 197,402.
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 – Prostate cancer is the cancer most frequently diagnosed in males: in 2008, 9559 cases were 
diagnosed (66.3 per 100,000 males, WSR). Worldwide, prostate cancer is the second most 
frequently diagnosed cancer in men (903,000 new cases, or 13.6% of the total number) and 
the fifth most common cancer overall. Nearly three quarters of the registered cases occur in 
developed countries. Incidence rates for prostate cancer vary by more than 25-fold 
worldwide, with the highest rates being observed in Australia/New Zealand (104.2 per 
100,000, WSR), Western and Northern Europe, and North America, largely because the 
practice of prostate-specific antigen (PSA) testing and subsequent biopsy has become 
widespread in those regions. 
 – Worldwide, cervical cancer is the third most common cancer in women, and the seventh 
overall, with an estimated 529,000 new cases in 2008. More than 85% of the global burden 
occurs in developing countries, with an incidence of more than 30 per 100,000 (WSR), where 
it accounts for 13% of all female cancers. In the Netherlands, cervical cancer incidence 
decreased by 1.4% per year from 2005 to 2008, to 699 new cases in 2008 (6.1 per 100,000, 
WSR). 
 
Cancer mortality6
 – In 2008, 40,993 people died of cancer in the Netherlands (125.4 per 100,000 person years, 
WSR).
 – During the period 2005-2008, the absolute number of deaths increased by 0.9% per year.
 – Corrected for population age and gender, cancer mortality decreased.
 – In the Netherlands, 3327 women died due to breast cancer in 2008 (20.0 per 100,000 
females, WSR); this represents a decrease of 13% from 2000 to 2008. Worldwide, the range 
of mortality rates of breast cancer is much smaller than the range seen in incidence 
(approximately 6-19 per 100,000, WSR) because of the greater chance of survival of breast 
cancer in (high-incidence) developed regions. Still, the estimated number of 189,000 deaths 
is almost equal to the estimated number of deaths caused by lung cancer (188,000 deaths).
 – In the Netherlands, the number of deaths due to colorectal cancer was 2466 in males (16.1 
per 100,000, WSR) and 2344 in females (11.2 per 100,000, WSR) in 2008. Worldwide, the 
highest estimated mortality rates in both sexes are in Central and Eastern Europe (20.3 per 
100,000 for males and 12.1 per 100,000 for females, WSR).
Total number of deaths due to breast, colorectal, lung, prostate cancer and 
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 – Because of the high mortality rate of lung cancer (with a mortality/incidence ratio of 86%) and 
the lack of variability in survival between developed and developing countries, the highest and 
lowest estimated mortality rates are found in the same regions as the highest and lowest 
incidence rates, both for men and for women. In the Netherlands, the lung cancer mortality 
rate is still increasing in females: in 2008, 3531 women died of the disease (22.2 per 100,000 
females, WSR). A decrease was seen in males with 6387 deaths in 2008 (42.0 per 100,000, 
WSR). 
 – In the Netherlands, skin cancer caused 766 deaths in 2008, of which 685 deaths were due to 
melanoma. Melanoma deaths in females increased by 55% in absolute terms to 297 deaths in 
2008. In males, death due to melanoma increased by 39% in absolute terms to 388 cases in 
2008. Worldwide, 6090 deaths can be contributed to melanoma. Mortality is again highest in 
Australia/New Zealand (3.5 per 100,000, WSR), followed by South Africa (3.0 per 100,000, 
WSR). Western Europe has a mortality rate of 1.5 per 100,000.
 – Prostate cancer was the cause of death for 2367 males in the Netherlands in 2008 (17.5 per 
100,000 males, WSR). Because PSA testing has a much greater effect on incidence than on 
mortality, there is less variation in mortality rates worldwide (10-fold) than is observed for 
incidence (25-fold), and the number of deaths caused by prostate cancer is almost the same 
in developed and developing regions. 
 – Cervical cancer deaths within the Netherlands decreased by 2.7% per year, to 244 new cases 
in 2008 (1.6 per 100,000 females, WSR). Worldwide, the mortality/incidence ratio was 52% 
and cervical cancer was responsible for 275,000 deaths in 2008, about 88% of which 
occurred in developing countries. In the Netherlands, the incidence/mortality ratio was 26%.
Cancer survival7 
 – Survival increased in the Netherlands: patients diagnosed between 2004 and 2008 survived in 
59% of cases compared to 47% of patients diagnosed between 1989 and 1993. In Europe, 
the five year relative survival rate for all cancers was 52% during the period 1995-1999. 
Overall, the UK and Eastern Europe showed a somewhat lower survival rate, also for the 
individual tumour types. The greatest increase in survival over time (from 1990-1994 to 
1995-1999) was found for prostate cancer (12.5%), followed by colorectal cancer and breast 
cancer (both 4.2%). 
 – In the Netherlands, women have a better survival than men (62% compared to 55%). In 
general, the lowest stage has the best survival rate for all tumours
 – Five year relative survival rate for breast cancer increased to 86% in 2008 (a 9% increase from 
1989-1993 to 2004-2008). In Europe, the five year relative survival rate for breast cancer 
showed an increase in all countries between 1990-1994 and 1995-1999, to 79.5% for 
patients diagnosed between 1995-1999, with rates ranging from 69.3% (Czech republic) to 
87.6% (Iceland).
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 – Survival of colorectal cancer in the Netherlands increased by 7% from 1989-1993 to 2004-
2008. The five year relative survival rates for patients with colon cancer and rectal cancer in 
the period 2004-2008 were 60% and 63%, respectively. For colorectal cancer, the five year 
relative survival rate increased by 4.2% to a survival rate of 53.5% in 1995-1999 in Europe in 
general, with rates ranging from 38.5% (Poland) to 59.7% (Switzerland).
 – The five year relative survival rate for lung cancer did not improve significantly and was 15% in 
the period 2004-2008. Within Europe, the survival of lung cancer showed small improvements 
in some countries. The highest survival rate was found in Western Europe. The European 
mean was 10.2% in 1995-1999, with rates ranging from 7.9% (Denmark) to 14.7% (Iceland).
 – Prostate cancer patients showed an increase in the survival rate of 22%, from 64% in the 
period 1989-1993 to 86% in the period 2004-2008, due to earlier detection of the tumour. A 
significant increase in the survival of prostate cancer patients was revealed in some countries. 
The survival rate in Europe as a whole was 73.9% and ranged between 47.7% (Denmark) and 
84.9% (Austria) in 1995-1999. 
 – Of all patients diagnosed with melanoma between 2004 and 2008, 87% survived the first five 
years, compared to 81% in the period 1989-1993. Females had a slightly better survival than 
males. The five year relative survival rate for melanoma was 85.4% for Europe as a whole 
during the period 1995-1999 and ranged from 63% (Poland) to 90.35% (Switzerland).
 – Cervical cancer had a five year relative survival rate of 66% (2004-2008) compared to 63% in 
1989-1993. 
Childhood cancer8,9
 – In the Netherlands only 0.6% of all cancers are paediatric cancers (children younger than 15 
years of age).
 – In total, 930 children were diagnosed in 2007/2008 in the Netherlands (161.1 per 100,000 
children under 15).
 – The types of cancer most frequently diagnosed in 2007-2008 in the Netherlands were 
lymphatic leukaemia (38.7 per 100,000, according to the European Standardized Rate (ESR)); 
astrocytoma (14.5 per 100,000, ESR); nephroblastoma/Willms’ tumour (11.3 per 100,000, 
ESR). Within Europe, the highest incidence rates were found for leukaemia, accounting for 
34% of all childhood cancers (42.4 per 100,000, WSR), and CNS tumours, accounting for 
23% (28.1 per 100,000, WSR). These represent the largest diagnostic groups among the 
under-15-year-olds.
 – In the Netherlands, survival increased by 8% from 71% in 1988-1992 to 79% in 2003-2007. 
The highest five year survival rate was found in the age group of 5-9 years old (with 81% 
being alive five years after diagnosis in 2003-2007). The ten year relative survival rate was 
75% (for children diagnosed in 1998-2002). For all childhood cancer types an increased five 
year survival rate was seen. The same increase was seen within Europe, where the survival 
has risen considerably over the past decades. Regarding the years 1995-2002, the data 
show an overall five year survival of 81% for Europe and similar values for the USA.
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Cancer prevention
The public health approach
Public health is a broad notion of the health of the total population, based on the recognition that the 
overall health and well-being is influenced by a wide variety of health determinants. The Dutch 
NCCP’s public health approach has been focused on collaborative actions between the various 
organizations regarding these determinants across many areas of society. 
What has been achieved?
Tobacco
Tobacco use has been linked to cancers of the lungs, lips, mouth, pharynx, larynx, oesophagus, 
stomach, pancreas, kidneys, bladder and some types of leukaemia. Tobacco use also increases the 
risk of some other cancers. Smoking is the single greatest cause of cancer and accounts for about 
30% of all cancer deaths. Besides increasing the cancer burden, smoking is associated with most 
cases of vascular diseases and COPD. This was the main reason why the Steering Committee of the 
Dutch NCCP identified discouraging smoking as the main objective in primary prevention for the 
period 2005-2010 in order to have a greater chance of achieving the goal of decreasing the 
percentage of smokers from 28% in the year 2000 to 20% in 2010. 
During that period, two prevention cycles were undertaken. Although the mass campaigns to 
discourage tobacco use were always organized in collaboration with the Municipal Health Services 
(GGDs: www.ggd.nl), not all of them participated, even in the second cycle. The GGDs that were 
active, were supported financially by a national campaign budget. During the Dutch NCCP period, 
the Dutch College of General Practitioners (NHG) www.nhg.nl publishes its first guideline on 
“Treatment of tobacco addition”. The national guideline on diagnosis and treatment of lung cancer 
was updated in 2009 (www.oncoline.nl). Following these guidelines, the care module on the 
treatment of tobacco addiction was incorporated into the existing care standards. 
KWF, the Netherlands Heart Foundation (Nederlandse Hartstichting), the Netherlands Asthma Fund 
(Astma Fonds) and the Expertise Centre for Smoking Prevention (STIVORO) initiated the National 
Programme for Tobacco Control (2006-2010). The aim of this programme was similar to the ambition 
of the Dutch NCCP on tobacco control: reducing the percentage of smokers to 20% by 2010. One 
of the key networks within this programme was the Public Private Partnership to Promote Smoking 
Cessation (PPP). This partnership of Dutch stakeholders in the treatment of tobacco addiction has 
been actively promoting the treatment of tobacco addiction for a long time. During the Dutch NCCP 
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period, the partnership revised the medical guideline on tobacco addiction (2009), developed the 
care module for tobacco addiction on the basis of which health insurance companies can contract 
tobacco addiction treatment (2009) and started the development of a quality register for 
professionals involved in the treatment of tobacco addiction. This register will be implemented in 
2011. 
The main achievements concerning tobacco control during the Dutch NCCP period were the 
realization of a smoke-free hospitality sector as of 1 July 2008 (the smoke-free workplace had 
already been implemented on 1 January 2004), an tax increase as of 1 July 2008, and the 
preparation for the reimbursement of tobacco addiction treatment, which will be implemented from 1 
January 2011.
 – As a result of the introduction of the smoke-free hospitality sector, combined with mass 
media campaigns and a tax increase on tobacco, the number of smokers decreased from 
28% in 2007 to 27% in 2008. In 2009 it went up again to 28%, however. The percentage of 
smoking in children aged 10-19 years dropped from 24% to 21%. Exposure to environmental 
smoke dropped from 155 minutes per day in 2007 to 141 minutes in 2008. 
 – In the preparation for the reimbursement of tobacco treatment, in 2008 a pilot was carried out 
in Utrecht by one of the main health insurance organizations (AGIS), partly funded by the 
Ministry of Health, Welfare and Sport. The results of this pilot showed that reimbursement is 
feasible, will be highly cost-effective and will increase the accessibility of treatment for 
low-income smokers. These results formed the basis for the recommendation from the Health 
Insurance Board (CVZ) in April 2009 to reimburse stop smoking programmes under the health 
insurance system10. The Minister of Health, Welfare and Sport adopted this recommendation 
in July 2009, and his decision is implemented on 1 January 2010. 
Despite these successes, the Dutch NCCP’s ambition to lower the percentage of smokers to 20% 
by 2010 has not been achieved. There are several reasons for this. One of the reasons is that in 
2008 and 2009 the tobacco industry raised a lot of resistance against the law for a smoke-free 
hospitality industry. Although this resistance was corrected by legal courts in 2010, it resulted in a 
delay in the implementation of the smoke-free law and the number of smokers increased again, from 
27% to 28% in 2009. An international analysis of the Dutch tobacco control policy (by Prof. Stanton 
Glantz e.a., 2010), concluded that the goals of the National Programme for Tobacco Control were 
too ambitious and the actions and level of funding did not correspond with the goal. Moreover, the 
programme failed to recognize the tobacco industry as a crucial vector of disease and an active 
opponent to the programme. Mass media campaigns focused on cessation rather than targeting 
non-smokers to reinforce the non-smoking standard. As a result, the non-smoking standard is not 
yet well-developed in the Netherlands. Future tobacco control should focus more on the non-
smoker, demoralize tobacco and tobacco use, and confront the tobacco industry.
Knowledge and perception of risk factors
Objectives
 – By 2010, the number of people who will be aware that an unhealthy lifestyle is a major factor 
behind the development of cancer will have increased by 15%, relative to the 2004 level.
 – By 2010, the number of people who take the view that they can influence their own risk of 
getting cancer by maintaining a healthy lifestyle will have increased by 5%, relative to the 
2004 level.
What has been achieved?
In 2006, KWF started a campaign entitled “Six times stronger against cancer” with the aim of 
increasing public awareness and knowledge about risk factors (especially lifestyle factors) for 
developing cancer. In 2007, research performed by TNS NIPO showed that 57% of the people 
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questioned thought that lifestyle plays an important role in the development of cancer. In 2009 this 
increased to 66%. However, people with an unhealthy lifestyle were found to attribute less 
importance to these factors than people with a healthy lifestyle. The percentage of people that agree 
that they can partially influence their own risk of cancer stayed the same between 2007 and 2009: 
62%. Evaluation of the effect of this campaign by Maastricht University (financially supported by 
KWF) showed that it had limited effect.
Obesity
Objective
 – By 2010, a maximum of 12% of the Dutch population will be obese.
What has been achieved?
In 2005, ten organizations signed the Covenant on Overweight and Obesity. The Ministry of Health, 
Welfare and Sport, together with the other social partners, aimed to tackle the overweight problem 
by encouraging exercise. The Covenant did not focus on nutrition. Its main goal was to slow down 
the increase in the percentage of overweight people to a maximum of 12% in 2010. In 2009 the 
National Compass showed that 11.2% of men aged 20 years and older and 12.4% of women aged 
20 years and older were obese. According to the figure below, the increase is still showing a growing 
trend. It can be assumed that in 2010 more than 12% of the Dutch population will be obese.  
In 2000, 9% of the Dutch population was obese (BMI > 30). According to the StatLine database of 
Statistics Netherlands (CBS), a slight increase in people with overweight (BMI >25) was seen 
between 2000 and 2009: from 44% to 47%. 
Food
Objective
 – By 2010, 30% of the population will eat an adequate quantity of vegetables and 40% will 
consume two pieces of fruit per day.
What has been achieved?
During the Dutch NCCP period, the Ministry of Health, Welfare and Sport did not focus on preventive 
activities to promote a healthy lifestyle. The Dutch Nutrition Centre, funded by the Ministry of 
Agriculture, Nature and Food Quality, and some other organizations promoted the consumption of 
fruit and vegetables and published some data in 2005-2006. Since then, no other data have been 
issued. The most recent comprehensive data available (1998) showed that 60% of the Dutch 
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population eat fruit and 70% of the population eat vegetables on a daily basis. Because of the lack 
of recent data, it is not possible to say whether the Dutch NCCP’s goals for nutrition have been 
achieved.
Exercise 
Objective
 – By 2010, 55% of the population will meet the Dutch standard for healthy exercise.
 – By 2010, up to 8% of the Dutch population fail to get enough physical exercise on any given 
day.
What has been achieved?
For the Ministry of Health, Welfare and Sport, physical exercise has been a spearhead of its policy. 
An example is the “30 minutes of exercise” campaign. The TNO monitor showed an increase in the 
percentage of adults meeting the standard, from 44.2% in 2000 to 58.7% in 2007. More recent data 
are not available. According to the figure below, the set goal had already been achieved in 2005. 
RIVM’s National Compass also revealed that (in 2005) the percentage of the Dutch population aged 
18 years and older for physical inactivity varies between 6% in summer and 9% in winter.
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Alcohol
Objectives
 – By 2010, up to 7% of Dutch adults will consume an average of more than three glasses of 
alcoholic beverages per day.
 – By 2010, up to 15% of young men aged between 15 and 25 will consume an average of 
more than three glasses of alcohol per day. The corresponding figure for girls will be the 
target value  
of 8%.
What has been achieved?
The report of VTV, the centre for explorations concerning future public health of the National Institute 
for Public Health and the Environment (RIVM), reports a steady number of problem drinkers. 
However, recent data on alcohol consumption among adolescents are not available.
Sunbathing 
Objectives
 – By 2010, 85% of the adult population will use some form of protection when sunbathing. 
 – By 2010, 90% of parents will protect their children against the sun’s rays (applying sun lotion, 
clothing/hat).
What has been achieved?
For many years now, KWF has been paying a lot of attention to this topic. Before the year 2000, the 
campaigns were focused on the general public, while for the last decade more attention has been 
given to children and adolescents. A study undertaken by KWF showed a decrease of 15% of 
protection when sunbathing among adults between 2000 and 2009, however. As a consequence, 
KWF conducted another campaign focused on adults. In 2009, 87% of parents protected their 
children against sunburn, which is a similar result as in 2000 (86%).
Healthy living also means paying careful attention to your body
Objectives
 – By 2010, Dutch people above the age of 55 will be more aware that early detection of cancer 
means an improved chance of survival. In numerical terms, in 2010 15% more people will be 
aware of this than was the case in 2004.
 – By 2010, more individuals in this target group will be capable of recognizing symptoms that 
could indicate cancer. In numerical terms, 10% more people will be capable of this than was 
the case in 2004.
Results
From 2007 onwards, KWF has been undertaking an annual campaign on “knowing the nine signs”, 
based on the European signals of the European Cancer Leagues (ECL). Maastricht University 
evaluated the effect of the campaigns (with financial support from KWF) and found that before the 
start of the first campaign (2007), 33% of respondents recognized the signals, while after the 
campaign (2009), 44% did.  
The attitude of people aged 55 years and older as regards the importance of watching out for 
symptoms which might indicate the presence of cancer increased by 10% between 2004 and 2010. 
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Conclusions 
 – Although some successes have been achieved, the development of a mutual framework 
based on common priorities agreed between all partners involved in primary prevention is still 
in the early stages. Joint priorities, actions and evaluations will help us gain a better 
understanding of what works and how cancer can be controlled in a more efficient way.
 – Tobacco control interventions have not been effective enough. However, the objective to 
reduce the percentage of smokers to 20% by 2010 was not realistic (see analysis of RIVM 
(www.rivm.nl/bibliotheek/rapporten/260601004.pdf). In addition, the tobacco discouragement 
policy was more or less ad hoc. To be more successful, a comprehensive policy plan 
spanning some decades will be necessary, including interventions such as intensive 
campaigns at national, regional and local level, the introduction of the reimbursement of stop 
smoking programmes and the increase of tax on tobacco.
 – The objectives concerning obesity, public awareness of the effects of healthy lifestyles, 
healthy food and drinks, enough excise and public knowledge of the nine signs seem to have 
been more or less achieved. This is primarily thanks to the very active role of KWF, the GGDs, 
RIVM and several NGOs in this field.
 – However, to maintain the targets or improve on them, comprehensive, long-term policy 
agreed between collaborative partners – including trend monitoring – will be necessary.
 – Primary prevention requires among others support for the development of an infrastructure 
and for increasing capacity at national, regional and local level. 
 – Based on sound research and clinical observations, preventive actions are now the only 
actions that help reduce the tremendous increase in incidence.
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Secondary prevention 
Screening attempts to identify cancer or its precursors early on in the disease process, before any 
symptoms appear. The goal of cancer screening is to reduce morbidity due to the disease and 
increase the likelihood of survival through early treatment. However, screening will only be beneficial 
if early treatment options offer some advantage over later treatments. Although it seems obvious that 
survival rates improve when cancer is detected, this is not always the case.
Organized screening programmes intend to recruit individuals in target groups, to decrease 
opportunistic screening and to decrease the costs of the healthcare system.
Decision-making associated with population-based screening programmes 
Objectives
Before 1 January 2005:
 – the Ministry will introduce a strict step-by-step plan which will serve as a focus for decision-
making regarding the introduction or amendment of national population screening 
programmes;
 – this step-by-step plan will be applied to decision-making regarding the possible introduction 
of population screening for colorectal cancer.
The Steering Committee considered this a priority and focused on the introduction of colorectal 
cancer screening. 
What has been achieved?
A special working group was installed with the task of identifying the 
bottlenecks and issuing recommendations with regard to the implementation 
of colorectal screening. The working group published its report in 2009. 
Various well-founded, concrete scenarios for implementation including 
consequences were outlined in the report. However, in spite of this clear and 
helpful report, and the conclusions published in the report of the Dutch 
Health Council (Gezondheidsraad), entitled “Bevolkingsonderzoek naar 
darmkanker” (Colorectal cancer screening)11, which propose starting with 
the implementation as soon as possible, the Ministry of Health, Welfare and 
Sport decided on 16 February 2010 to postpone the introduction to a later 
date, beyond the year 2010. 
In the Netherlands, cervical cancer screening started in the 1980s and was performed by the GGDs. 
From 1995 onwards, collaboration with the IKCs was required. Breast cancer screening was 
implemented in 1990 at regional IKC level.
Direction and implementation of population screening
Objectives
As of 1 January 2006:
 – the two present separate organizations for the implementation of population screening for 
cancer will be replaced by a single organization within which all of the functions for population 
screening will be integrated. This organization will also be charged with the implementation of 
a new population screening programme for cancer, which has yet to be designed;
 – the new organization for the implementation of population screening for cancer will consist of 
a national director and nine regional screening organizations, which will maintain close 
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relationships with the other regional organizations involved;
 – the supervision of the various parts of the implementation organization and their individual 
accountability will be based on the principles of “healthcare governance”.
What has been achieved?
 – From 1 January 2010, a single organization has been responsible for the realization of 
population-based breast cancer and cervical cancer screening, managed by RIVM.
 – RIVM supervises the organization, financing, quality policy and monitoring of the screening 
programmes, according to national criteria.
 – Reorganization of the geographical areas resulted in five implementation regions, each with a 
similar organization based on the principles of “healthcare governance”.
Five regions for breast cancer and cervical cancer screening, integrated into a single national 
organization, led by RIVM
Transition from population screening to the regular care system
Objectives
 – In mid 2006, quality criteria will be established and imposed on the transition of patients from 
population screening programmes to regular diagnosis and treatment. In addition, the 
responsibilities of all those involved will be established, in order to achieve sufficient 
throughput. 
 – By the end of 2006, each of the regions will have calculated the capacity that they require (in 
terms of professionals and facilities) to adequately diagnose and treat the referred patients.
 – At the start of 2007, the quality criteria relating to throughput will be incorporated into the 
conditions governing care contacts with insurance companies.
 – By the end of 2008, the capacity of the regular care system will match the supply generated 
by population screening programmes, and the quality criteria will have been met.
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Main results
The Dutch NCCP’s Steering Committee prioritized this topic. A working 
group published a report in 2008 entitled “Aansluiting van screening naar 
curatieve zorg. Praktische problemen en mogelijke oplossingen” (Alignment 
of screening and curative care. Practical problems and possible solutions), 
including an analysis of bottlenecks and recommendations.
Main bottlenecks identified
 –  Referral, following screening, to the hospital/clinic for further diagnostics 
and treatment is not organized in a structured way.
 –  Responsibilities of and communication between the various 
stakeholders are unclear.
Most relevant recommendations
 – Monitor the transition between screening and hospital care.
 – Identify indicators including waiting times.
 – Include these indicators in the project of the Dutch Health Care Transparency Programme 
(www.zichtbarezorg.nl).
 – The screening organizations should conclude agreements with breast cancer and 
gynaecology cancer outpatients’ departments to guarantee short waiting times. In addition, 
this will ensure that these hospitals will be able to better plan the capacity of professionals.
 – Improve in the relationships with GPs.
What else has been achieved?
 – The National Breast Cancer Working Group (NABON) identified quality indicators by 2009.
 – The Dutch Health Care Transparency Programme has adopted these. 
 – Collaboration between hospitals has improved the available capacity of professionals.
 – Relationships with GPs have not yet been structured. 
Population screening and information provision 
Objective
 – By the end of 2006, the registries and information systems that are vital to the control of 
population screening programmes and the follow-up process will be so accessible and 
mutually compatible that to all intents and purposes users will experience it to be a single, 
integrated information system. Such users should be able to timely the data that they need to 
perform their duties.
What has been achieved?
 – Due to the reorganization of the screening programmes, there was some delay in the 
provision of data for 2007 and 2008. 
 – Annual monitoring and results on breast cancer screening are published by Erasmus 
University Rotterdam.
 – In 2010, a first national evaluation of cervical cancer screening was published.
 – The linking of data of the five screening organizations and those of the population-based 
national cancer registry of the VIKC guarantees annual evaluations and will make additional 
research possible. 
Turnout for population screening 
Objective
 – The population of the Netherlands will be more aware of the importance of participating in 
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population screening programmes, and of the pros and cons of test kits and of check-ups in 
private clinics.
What has been achieved?
Breast cancer
 – The participation rate of breast cancer screening has been ≥ 80% (the highest rate in Europe) 
since 2000 and is increasing slightly.
 – The referral rate has increased from 14 per 1000 screened women in 2004 to more than 18 
per 1000 in 2008.
 – As a consequence, the percentage of women actually diagnosed with cancer among those 
referred has decreased from 43 of all referred women to 30 in 2008.
Breast and cervical cancer screening in the Netherlands
1998-2000 2001 2002 2003 2004 2005 2006 2007 2008
Attendance of breast cancer 
screening (%)
78,5 78,7 79,1 80,8 80,8 81,7 81,8 82,4 82
Positive predictive value of 
breast cancer screening (%)
43 38 38 37 35 34 32 31 *
Referral rate (per 1000) after 
breast cancer screening
10,9 13,8 13 13,1 14,1 14,5 16,1 18 *
Attendance cervical cancer 
screening (%)
61 62 64 66 65,6 65,5 66 * *
*=not available
Source for breast cancer screening: Landelijk Evaluatie Team Bevolkingsonderzoek Borstkanker (LETB)
Source for cervical cancer screening: RIVM
Cervical cancer
 – The participation rate of cervical cancer screening is 66%.
 – RIVM is looking for options to make people more alert about the pros and cons of commercial 
check-ups. This is not yet a high priority.
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Financing secondary prevention
Objective
As soon as possible, but in any event before the end of 2006: 
 – It will be established how the future financing of population screening programmes will be 
secured.
Results
 – The centres for clinical genetics focused on cancer have developed evidence-based 
guidelines.
 – The genetic tests are now being structurally financed.
Conclusions 
 – The reorganization of the screening programmes into a single structure has been realized.
 – The journey following breast cancer screening has been improved.
 – Indicators to monitor the screening procedures and the outcome have been identified.
 – The monitoring results are now published annually, supported by an optimum link between 
the screening database and the Netherlands Cancer Registry (NKR).
 – No attention has as yet been paid to commercial test kits and medical check-ups in private 
clinics.
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Cancer care
Improvement in care: general data
Objectives
 – By 2010, the five year survival rate for cancer patients will be 20% higher than in the year 
2000.
 – By 2010, cancer patients’ satisfaction regarding how they are dealt with, their treatment and 
their aftercare will have increased by 20% relative to 2005. 
Five year relative survival of cancer in the Netherlands (age standardized)
  1989-1993 1994-1998 1999-2003 2004-2008 difference between 
1989-1993 and 
2004-2008
All cancer types 47% 51% 54% 59% +12%
male 40% 45% 49% 55% +15%
female 55% 57% 59% 62% +7%
Breast cancer 77% 80% 84% 86% +9%
Prostate cancer 64% 77% 82% 86% +22%
Colorectal cancer 54% 55% 58% 61% +7%
Colon cancer 55% 56% 58% 60% +5%
Rectal cancer 52% 56% 57% 63% +11%
Lung cancer 13% 12% 12% 15% +2%
Non Small Cell Lung Cancer 15% 14% 14% 16% +2%
Small Cell Lung Cancer 4% 4% 4% 6% +2%
Melanoma 81% 84% 86% 87% +6%
Cervical cancer 63% 64% 65% 66% +4%
Source: Netherlands Cancer Registry, VIKC
What has been achieved?
The relative five year survival rate for patients with cancer did improve by 5%, from 54% in the period 
1999-2003 to 59% in the period 2004-2008. 
Cancer patients’ satisfaction measurement has not been undertaken nationwide. However, a 
decision has since been made to develop another, more informative instrument: the CQ index for 
cancer patients. This instrument will be ready by the end of 2010. A CQ index for breast cancer 
patients (the most common type of cancer in the Netherlands) has been partially validated and is 
starting to be implemented in 2010. This is being done in collaboration with the National Breast 
Cancer Patients’ Organization (BVN). In addition, NFK, together with the Haemato Oncology 
Foundation for Adults in the Netherlands (HOVON), has developed another instrument to measure 
the information provided to haemato-oncological patients and their experiences during their journey 
(see the websites www.nfk.nl and www.hovon.nl). The implementation of this instrument started in 
2008, and the health insurance companies are aiming to only contract hospitals which use this 
quality instrument in the future. 
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Quality and accessibility of cancer care
Working group activities
With regard to cancer care, the Steering Committee decided to select, out of the 39 actions 
formulated in the NCCP programme for 2005-2010, one spearhead: the quality and accessibility of 
cancer care. A multidisciplinary working group was set up, which was to approach this theme from 
various angles.
What has the working group achieved?
Realizing that the oncology landscape will undergo radical changes, the main partners in this field 
which are represented in the working group – cancer patients (and their associations), professionals 
and insurance companies – formulated their assignment as follows: “Which changes in the 
structure (organization) and quality of oncological care are necessary in order to guarantee the 
accessibility of optimal cancer care and an optimal care system for all patients in the future?” 
Therefore, five main topics were identified: 
 – Structure and organization of cancer care
 – Quality of cancer care
 – IT and communication
 – Oncological care and the free market
 – Finance and policy
The recommendations were published in the report of Working Group 4, 
“Bevorderen kwaliteit en toegankelijkheid kankerzorg” (Promoting the quality 
and accessibility of cancer care).
Most relevant recommendations
 –  The patient’s journey (pathway) has to be well-defined with regard to the 
responsibilities of care providers:
 –  The patient needs to know who their contact person is in the hospital 
and outside, and this will preferably be limited to only one or two 
persons.
 –  Communication between all care providers should be coordinated by 
these contact persons and will require a better IT system.
 –  Collaboration between care providers is indispensable in oncological 
care.
 – To ensure better evaluation, structure and organization should be taken into account in 
addition to volume per hospital. These indicators should be part of the basic cancer registry.
 – The Ministry of Health, Welfare and Sport should be asked to support the implementation of 
the electronic patient file system at national level.
 – A future-proof financial system needs to be in place to guarantee optimal accessibility and 
quality of cancer cure and care.
These recommendations were discussed during the conference “The oncology of the future”, which 
was held on 22 January 2009 and attended by more than 250 care providers and representatives of 
these organizations. A summary of this conference is available on www.npknet.nl and can also be 
found in part II of the progress report. Many of these organizations, including national associations of 
medical specialists, such as NVMO, NVCO, NVRO, NVvO and national psychosocial oncologists, 
V&VN, NFK, IGZ, VIKC, KWF and ZN, have adopted some of these recommendations in their policy 
plans.
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Interview with Aart van Bochove, general physician/oncologist 
“You always have to ask yourself: what are the interests of the patient?”
One could say that oncological care is in his blood. Aart van 
Bochove has been working for 22 years as a medical oncologist 
at Zaans Medisch Centrum (ZMC) in Zaandam. He has also 
served in many other positions in the field of oncological care 
and continues to do so today. In his capacity as chairman of a 
working group on the quality and organization of oncological 
care, he is closely involved in the National Cancer Control 
Programme (Dutch NCCP). Van Bochove believes that effective 
and accessible oncological care is a matter of life and death, 
both figuratively and literally.
Of course, Van Bochove is not alone in his pursuit of quality and accessibility. It is an ambition that is 
shared by the Dutch NCCP. Two years ago, the Dutch NCCP working group chaired by the medical 
oncologist delivered its end product: a vision document on the future of oncology was presented 
during a Dutch NCCP congress at the beginning of 2009. “Our report is not a blueprint with ready-
made solutions; it is a vision document containing a number of statements that are important for 
oncological care”, says Van Bochove.
One of the most significant concepts that the document puts forward is that the interests of the 
patient should always be central. “That may sound self-evident, but it’s not”, says Van Bochove. 
“After all, there are frequently other interests to take into account: those of the physician, the 
hospital and the health insurer. That’s why we say that as soon as a discussion about a particular 
aspect of oncological care arises, you have to ask yourself: what are the interests of the patient?”
The document also discussed the size and scope of oncological care. “Due to the fact that some 
hospitals are simply too small and the field is too specialized, it isn’t conceivable for all hospitals to 
offer comprehensive oncological care”, says Van Bochove. “On the other hand, it isn’t feasible either 
for care to be concentrated in just a small number of hospitals. There are simply too many cancer 
patients to be treated at just a few centres. Ideally, we want to provide care as close to the patient’s 
home as possible. Therefore, we can conclude that effective cooperation and a clear division of 
responsibilities between hospitals is extremely important.”
The working group chaired by Van Bochove does not shy away from controversy. “One of our 
findings was that oncological care does not lend itself to competition in a free-market environment. 
But this was precisely the approach that the Ministry of Health, Welfare and Sport was promoting in 
the sector at the time. This very same Ministry is one of the parties involved in the Dutch NCCP, so 
this conclusion of ours was quite controversial. Thankfully, we have since noted that our message 
has made quite an impact. These days, there is broad consensus that leaving everything up to the 
market may not be the best solution after all.”
Van Bochove’s personal involvement in the Dutch NCCP began in spring 2007 when he was asked 
to chair one of the organization’s working groups. Though he is now a staunch supporter of the 
Dutch NCCP, he does have a few critical comments. “The main benefit of the Dutch NCCP is that all 
parties in the oncological care sector are brought together in a single structure. Though this joining 
of forces is an advantage in many respects, it also represents a risk. It is important that these parties 
do not remain stuck at the strategic level, but that they achieve practical results.”
In this regard, Van Bochove sees the Dutch NCCP Monitor as an excellent tool because it clearly 
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indicates the results being achieved in each area across the oncological care sector. The fact that 
many of the aims and targets set by the programme still have not been achieved does not worry Van 
Bochove. “You don’t start turning a supertanker around in a harbour just like that. It takes time. So 
there’s really no reason for us to be discouraged; we’ve taken a number of steps in the right 
direction. What we need to do now is keep working together to hit those targets.”
There is certainly still much to be accomplished with regard to lobbying against smoking. “What 
strikes me is that we take such a haphazard approach to one of the most significant threats to public 
health in the Netherlands”, Van Bochove sighs. “We allow cafe owners to shape the discussion on 
this important issue. Of course, it’s an incredibly complicated subject, but if you see how much 
damage is being caused by smoking, it’s high time that a much stronger position is taken against 
smoking. This is also one of the ambitions of the Dutch NCCP.”
For the Dutch NCCP, cooperation is written with a capital C. Van Bochove, who chaired the Dutch 
Society for Medical Oncology (NVMO) from 2001 to 2007, has also contributed to this aspect of the 
Dutch NCCP’s activities. As NVMO chairman he was one of the initiators of SONCOS, the 
Foundation for Cooperation in Oncology. This organization brings together medical oncologists 
(NVMO), surgeons (Dutch Society for Oncological Surgery working in the field of oncology), and 
radiotherapists (Dutch Society for Radiotherapy and Oncology). “I strongly supported the merger of 
the various scientific associations for oncological specialities”, says Van Bochove. “As oncology 
increasingly became a multidisciplinary field, the associations did not cooperate with each other at 
all. Thankfully this has begun to be rectified with the establishment of SONCOS.”
Van Bochove believes that it is essential for the scope of the Dutch NCCP to cover ‘current issues’ 
as well as the numerous new developments in the sector. “Despite the good results that we’ve 
achieved in the treatment of a number of specific tumour types over the past few years, the fact is 
that many patients experience relapses or are incurably ill. Although this is not such a glamorous 
topic, it is imperative that we continue to focus our attentions on this large group of people. Of 
course, it is much more exciting to report that a treatment has been developed to increase the 
chance of survival in patients with a certain type of tumour, even if it is a rare type.”
“The Dutch NCCP explicitly states that patients who have received treatment and subsequently 
recovered, at least in an oncological sense, require more effective aftercare”, Van Bochove 
continues. “At the moment this is just not happening enough. Although psychosocial care has 
indeed improved, there is still much more that can be done in this field. As a physician, you can’t just 
turn and walk away after a patient has been treated successfully. In doing so, you’ve only completed 
half the work. There is still a whole aftercare programme to be carried out, which is as critically 
important for the patient as the successful treatment was.”
Other objectives concerning quality and accessibility of care
Objectives
 – By 2005 the quality criteria for multidisciplinary coordinated chain care will be ready.
 – By 2006, an inspection/accreditation system will be ready, and the implementation of these 
criteria will be tested in a pilot study. In addition, the working methods of the oncology 
committees, the multidisciplinary patient discussions and the consultant services will be 
assessed at national level.
 – By 2006, work will have been completed on a description of the tasks and responsibilities of 
professionals with regard to education and psychosocial care for patients in hospitals. This 
will be part of the multidisciplinary assessment, or inspection/accreditation of oncological 
care.
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 – By 2010, all hospitals in which cancer is diagnosed and/or treated will have undergone 
inspection/accreditation. Primary care will definitely be included in this process of inspection. 
The results of this assessment should be available and comprehensible to those requiring 
care.
What has been achieved
A peer review system and an electronic self-evaluation guide, by way of an internal audit system for 
the organization of oncological care (according to criteria approved by the medical professionals), 
have been updated and set up at national level, supported by the IKCs. Most of the hospitals have 
been peer reviewed during the past few years or are working on achieving this between 2010 and 
2012. This system promotes and clarifies the multidisciplinary approach, the communication and 
agreements between the various organizations (e.g. hospitals and radiotherapy centre, hospital and 
GP) and the available capacity of specialists, care providers and professionals.
Pilots on tumour-specific pathways have been undertaken by the IKCs since 200712,13. These 
pathways serve as an implementation and monitoring tool for all existing national guidelines and 
indicators and include the recommendations issued by Working Group 4 and by IGZ in its report 
“Zorgketen voor kankerpatienten moet verbeteren” (Care chain for cancer patients must improve)1; 
the monitoring system periodically includes patients’ focus groups (at hospital level). 
In 2010, KNMG, the Royal Dutch Medical Association, published a support tool with regard to 
sharing responsibilities in the context of collaboration in care. A checklist with 13 tips summarizes 
the report entitled “Checklist met 13 concrete aandachtspunten bij afspraken over 
verantwoordelijkheden” (Checklist with 13 concrete points for attention in agreeing 
responsibilities).14
Special attention has been given to the terminal phase of patients by developing the “pathway of 
dying”. In 2009-2010 this pathway is being implemented nationally, supported by the IKCs.
As the Ministry of Health, Welfare and Sport is in favour of care standards (due to favourable 
experiences with care standards for diabetic patients) it presented NFK with the opportunity to 
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analyze the possibility of a cancer care standard for cancer patients, something that resulted in the 
NFK report “Verkenning Zorgstandaard Kankerzorg” (Explorations for a care standard for cancer 
care)15. As a result of this analysis, NFK, together with other partners, will be trying to realize a 
generic standard. To avoid duplicates, the participants in the two projects on care standards and 
pathways are collaborating intensively. 
The development and registry of indicators on process, structure and outcome have been realized 
by the collaborative project of the Dutch Health Care Transparency Programme on breast cancer. 
VIKC is responsible for facilitating the process of development and registry of the indicators on 
cancer. Since 2008 the IKCs have been giving an overview of several indicators on the quality of 
oncological care per hospital (the so-called “ONCOMONITOR”, www.ikcnet.nl). The indicators take 
volume and outcome into account and are based on the items which are registered in the NKR in 
relation to the main tumour groups. These data are provided nationally in aggregated way. The 
hospitals obtain their own data.
Concentration of treatment
Objectives
By 2005, a committee will have been appointed and tasked with:
 – Developing quality criteria for the allocation of tasks and concentration in oncology.
 – Drawing up a plan in relation to implementation, and assessing implementation on the basis 
of the above-named criteria.
 – Indicating the repercussions if the criteria have not been met.
 – Producing a report, which will include details of what is expected of each of the parties 
involved in implementation.
What has been achieved?
This issue is still unresolved as not enough quality criteria are available to decide which main factors 
are responsible for good outcome, NVCO, the Dutch Society of Surgical Oncology, is urging more 
and more for the concentration of treatment of complex and less common tumours. 
The report “Kwaliteit van kankerzorg in Nederland” (Quality of cancer care in the Netherlands) by 
KWF’s Cancer Signalling Committee (published in 2010) states recommendations on concentration 
of treatment. Concentration should take place on the basis of criteria concerning hospital 
infrastructure, volume and degree of specialization, and demonstrably good care outcomes. The 
report includes a plan with a more detailed description of the parties involved and of the tasks and 
responsibilities in the implementation.
In some IKC regions, managed clinical networks (agreements between hospitals about who is doing 
what, how and in which situation) have recently been set up for oesophagus cancer, pancreatic 
cancers and ovarian cancers. Thanks to the super specialization of medical specialists, 
multidisciplinary teams of experts in certain types of cancer are being formed and they are 
increasingly providing advice to the general hospitals through videoconferencing, facilitated by the 
IKCs.
This shift in consultancy services will have its implications for the structure and organization of 
general hospitals.
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Care: supply and demand
Objectives
 – By 2005, a scenario will have been developed for the period from 2005 to 2020. This will 
indicate the requisite capacity of the healthcare system, based on the anticipated flow of 
patients from the population screening programmes and the increased number of cancer 
patients.
 – By 2006, an implementation process will be ready.
 – By 2010, there will a good balance between supply and demand in the oncological care 
sector. This will apply to all cancer patients, and to those for whom a diagnosis of cancer is 
being considered. This is measurable through waiting lists, throughput times, and assessment 
of the implementation of guidelines for diagnosis and treatment.
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What has been achieved?
 – Waiting times and throughput times are part of the indicators registered for some tumours in 
VIKC’s NKR; they are also being registered separately by hospitals and insurance companies. 
 – Treatment according to guidelines can be measured through the NKR and the indicators 
defined by the national multidisciplinary working groups. 
Guideline for adherence per cancer type
Percentage in agreement with the 
guideline (2007)
Guideline for colon cancer
At least 10 lymph nodes investigated/resected 65.1%
Adjuvant chemotherapy 73.1%
Guideline for rectal cancer
Pre-operative radiotherapy 82.6%
Guideline for bladder cancer
Radical lymph node dissection 27%
Development of guidelines
Objectives
By 2005, procedures will be available for the development, adjustment, implementation and 
assessment of guidelines, in terms of both methodology and content. The guidelines will focus on a 
number of specific components, such as: 
 – education;
 – elderly patients (co-morbidity).
During implementation, consideration will also be given to: 
 – allocation of diagnosis, counselling and follow-up tasks between primary and secondary 
healthcare;
 – familiarizing primary healthcare providers with the guidelines.
Type of treatment T1M0 breast cancer  females 15-75 jaar
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68,9 68,9 68,8 69,0
38,7 38,4 38,0 32,1
30,4 30,7 30,4 30,2
0%
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80%
100%
2000 2001 2002 2003 2004 2005 2006 2007
breast conserving amputation/ablatio other
Source: Netherlands Cancer Registry, VIKC
40
A procedure will be established for familiarizing individuals with new and updated guidelines.
By 2005, it will be clear which party or parties will bear responsibility for overall control. 
By 2005, the collected guidelines will be available via www.oncoline.nl. There will also be links to the 
monodisciplinary guidelines and the NHG standards www.nhg.nl.
By 2005, the financing of multidisciplinary guideline development will have been clarified.
By 2005, a national summary of the guidelines that have been assessed (including the results) will be 
available via www.ikcnet.nl.
By 2007, the procedures will have been assessed.
By 2005, the cancer registry will be able to collect the additional data required for the assessment. 
There will be a plan for efficient assessment of the guidelines. This plan will be updated annually.
By 2005, there will be a link between the cancer registry and the Local Authority’s Residents Registry 
(GBA), to display details of patient survival.
What has been achieved?
 – The procedures for the development, implementation and evaluation of guidelines are 
available and are being used by VIKC, in support of the multidisciplinary oncological 
guidelines (www.oncoline.nl). See also part II. These procedures are ranked among the top 
three of procedures available in Europe (www.cocancpg.eu).
 – More than 150 national guidelines are publically available on www.oncoline.nl, www.pallialine.
nl, www.herstelenbalans.nl, www.ikcnet.nl/sib and www.stg.nl/index.php?page=271&lang=1.
 – The financing of multidisciplinary guideline development has been clarified but the costs are 
far from being covered. The monodisciplinary medical associations, the Ministry of Health, 
Welfare and Sport and the IKCs are each providing financial support for part of the 
development and updating of guidelines.
 – Evaluation of guidelines and survival data (by linking the NKR with the GBA) are available on 
www.npknet.nl/monitor and www.ikcnet.nl/cijfers.
Diagnostic phase and staging
Objectives
 – By 2005, a summary of the (European) cancer code for the early diagnosis of cancer will be 
available on www.ikcnet.nl.
 – By 2005, there will be an implementation plan for such early detection.
 – In 2007, there will be an initial assessment of people’s familiarity with this topic. It will be 
possible to measure this in terms of doctor-related delay (referral) and through trend analyses 
of tumour stages.
 – From 2005, as part of the development and adjustment of national guidelines, there will be a 
systematic focus on the allocation of tasks in terms of early and later diagnosis.
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Goals achieved
 – The European cancer code “Know the 9 signs” (see primary prevention chapter) has been 
adopted by KWF and related campaigns are now part of its policy plan.
 – Tumour stages have been collected by the NKR since 1989. 
 – No major stage changes have been observed over the period 2000-2007.
 – The increase in the percentage of stage I in breast cancer is mainly due to a change in the 
definition of the stage (TNM Wittekind 2004).
 – The increase in the percentage of stage I in prostate cancer between 2000-2007 is related to 
the increased use of PSA detection.
 – For colon cancer, no relevant changes in staging were observed over the period 2000-2007. 
For rectal cancer, the percentage of stage I-II patients decreased, something that mainly 
reflected a stage migration due to improved staging procedures (CT scan, MRI, endo 
ultrasound). 
 – The percentage of stage IV in lung cancer is increasing, mainly due to the introduction of the 
PET scan, which has improved the detection of metastasis compared to the conventional CT 
scan.
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Stage at diagnosis - prostate cancer-
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Stage at diagnosis - non small cell lung cancer (NSCLC)-
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Treatment phase
Objectives
 – By 2005, there will be a national coordination point for oncological trials. Its responsibilities 
will include keeping the trial summaries up to date and accessible via the Internet. 
 – By no later than 2006, agreement will have been reached concerning the adequate financing 
of data management and the responsibilities of the parties involved with regard to the 
performance of research and data management.
 – The procedure for drawing up and amending guidelines will speed up the flow of results from 
clinical research to daily practice.
 – In 2007, more than five percent of trials will focus entirely on patients above the age of 70.
What has been achieved?
 – VIKC is playing a role in the coordination of investigator-driven trials. KWF is funding data 
management.
 – Concerning adequate financing of data management and parties conducting research and 
data management, important steps have been taken. 
 – More and more attention is being paid to the development of trials for elderly patients.
 – A regional trial database informing patients on ongoing trials has been developed as part of a 
pilot project. The trial database is currently being expanded to the national level
Aftercare
Objectives
 – From 2005 onwards, a new chapter on aftercare will be added to the procedure for drafting 
new guidelines or updating existing ones. This will address the issues of when and how 
screening will be carried out, and for what. The follow-up screening will include an 
assessment of the patient’s psychosocial situation and the later effects of treatments, 
relapses and metastases.
 – During implementation of the guideline, the allocation of screening-related tasks between 
primary and secondary healthcare will be determined at local level. This will involve who does 
what, and when and how this will be communicated to other professionals and to the patient.
 – From 2005 onwards, where relevant, the process of developing, implementing and adjusting 
guidelines will include consideration for palliative and terminal care, and the adequate 
handling of issues surrounding euthanasia.
What has been achieved?
 – National guidelines on rehabilitation www.herstelenbalans.nl / www.oncoline.nl, on going back 
to work and on detection of the need for psychosocial support using the Distress 
Thermometer (Lastmeter: www.lastmeter.nl) are available.
 – The development of the guideline on aftercare is only in its early stages but is broadly 
supported.
 – Survivorship is receiving more and more attention as the prevalence of survivors is increasing 
enormously. 
 – The allocation of tasks has not yet been described in all guidelines.
 – The IKCs have supported not only the development but also the updating (in late 2010) and 
implementation of guidelines for palliative care.
Conclusions 
 – Many different associations and organizations have included objectives into their own policy 
plans recognizing the bottlenecks of these recent years.
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 – Survival rates are improving but not as fast as in other developed European countries.
 – Important steps forward with regard to structural and organizational aspects are being taken 
and implementation can be expected in the near future (peer review, pathways, cancer care 
standards).
 – Monitoring systems using indicators and available registry systems have been developed and 
the first results are available.
 – Guidelines on diagnosis, treatment, aftercare and palliative care are available and the 
procedures to develop these are of very high quality.
 – The structure of data management and the implementation of trials have been improved.
 – However, to guarantee optimal quality of cancer care and accessibility with a view to:
 – an increase in the absolute number of cancer patients;
 – an increase in the absolute number of survivors;
 – an increase in refined and more sophisticated diagnostic and treatment possibilities;
 – financial bottlenecks,
 – the priorities defined by Working Group 4 will need to be translated to concrete objectives 
and actions.
Interview with Chiel Bos, former director of the Dutch Association of 
Healthcare Insurance Providers
“Funding has to be linked much more effectively to quality of care”
As director of the Dutch Association of Healthcare Insurance Providers 
(Zorgverzekeraars Nederland, ZN) from early 1999 until spring 2008, Chiel 
Bos was one of the initiators of the National Cancer Control Programme 
(Dutch NCCP). Although many of the programme’s aims have not yet been 
achieved, Bos focuses on the positive side of things. “Without a doubt, 
oncological care has improved thanks to the Dutch NCCP. The main 
change for the better lies in the fact that the various disciplines now work 
together much more effectively than before. People used to say that you 
could only receive high-quality oncological care in university hospitals and that other 
institutions didn’t count. Thankfully, we’ve come down from our ivory towers on this issue.” 
Bos has gained plenty of recognition within the healthcare sector. He is now working as an 
independent advisor and can draw on a wealth of managerial experience. Bos is also vice-chairman 
of the National Council on the Quality of Healthcare, and is investigating the possibilities for the 
establishment of an ‘eHealth’ programme at VU University in Amsterdam. Bos is a man with vision 
and an outspoken opinion, and he is not afraid to share either of them.
“What’s great about the Dutch NCCP is that this is an initiative of the sector itself. The Dutch Cancer 
Society, the Dutch Federation of Cancer Patients’ Organizations, the Association of Comprehensive 
Cancer Centres and various health insurers have committed to working together to ensure the best 
possible oncological care throughout the sector, and throughout the country. The Ministry of Health, 
Welfare and Sport declared its support for the initiative and wanted to play an active role in the 
programme. The great benefit of the Dutch NCCP lies in ensuring that the patient is represented 
much more effectively and is of central importance within the oncological care sector.”
The Dutch NCCP asserts that both the quality and accessibility of care has to be the same for 
everybody. “The level of care should be the same for every patient, regardless of whether you live in 
the provinces or next to Antoni van Leeuwenhoek Hospital in Amsterdam”, says Bos. “Patients 
should be able to receive care as close to home as possible and be referred to a specialist centre if 
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necessary. Standardization is also an important principle. It’s not acceptable for a patient with a 
tumour that in one hospital he would be operated, while in another he would undergo radiotherapy 
for the same tumour.”
Bos believes that it was only logical for the Dutch Association of Healthcare Insurance Providers – of 
which he was director at the time – to be involved in the Dutch NCCP from its inception in 2005. “It 
was at this time that healthcare insurers were also starting to set their own requirements regarding 
the quality of care. We didn’t just want to collect premiums and pay care institutions; we also wanted 
to discuss the accessibility and content of the care provided. Our emphasis on, for example, 
accessibility played a prominent role in the establishment of special breast cancer outpatient clinics. 
These clinics allow patients to be diagnosed within a day.”
The health insurers are not only one of the five parties participating in the Dutch NCCP; they also 
finance the programme together with the Ministry of Health, Welfare and Sport. However, as far as 
Bos is concerned, this has never led to a conflict of interests. “Not at all! It’s very simple: if you wish 
to have high-quality care, someone has to pay for it. It’s better to provide a patient with the best 
treatment possible rather than opt for a cheaper solution that doesn’t have the desired effect. Why? 
Because in the end, it’ll end up costing more. Not to say that effective treatment has to be 
expensive, of course. What is expensive, anyway? Psychosocial treatment costs a lot of time and, by 
extension, money, but it benefits the patient’s mental condition and therefore his health as well.”
Bos knows what he’s talking about due to his position as chairman of the Dutch NCCP working 
group on psychosocial care. “Health insurers have included psychosocial care in their reimbursement 
schemes since 2006. This recognition is very important for the development of this form of care, 
which is one of the spearheads of the Dutch NCCP. In addition to treating the physical disease, 
attention must also be paid to the psychosocial problems experienced by patients after finding out 
they have cancer. After an operation, it can sometimes take years for a patient to regain his mental 
balance. Nurses and psychologists can play an important role in ensuring that the path to recovery is 
as easy as possible.”
Bos is critical of the Dutch NCCP’s apparent lack of activity of late. “After an ambitious start, in 
which much was accomplished in a short period of time, the programme seems to have lost steam. 
The parties involved have to provide new impetus and energy to the programme. The best way of 
doing this is to develop a new five-year programme with new spearheads. What sort of spearheads 
do I mean? One example is more efficient use of modern communication technology, such as 
utilizing electronic patient files in order to exchange information quickly and easily. Other spearheads 
could include improving the system that refers patients to specialist centres and changing 
regulations pertaining to costs and funding.” 
“Funding has to be linked much more effectively to quality of care”, Bos emphasizes. “The wrong 
incentives have arisen over the past few years due to the introduction of so-called ‘Diagnosis 
Treatment Combinations’. Something is wrong if a hospital opts to perform an operation instead of 
radiotherapy just because it receives more money by carrying out the former option. As a hospital 
you should never be tempted to do this!”
Bos really hopes that the National Cancer Control Programme will continue. “The best course of 
action would be for the Ministry of Health, Welfare and Sport to promote and facilitate the Dutch 
NCCP much more than at present, for example through a different form of funding. It is also 
important for the Ministry to promote the Dutch NCCP’s recommendations and to avoid allowing the 
agenda to be set by comments made in the Lower House of Dutch Parliament, which are often 
fuelled by action groups representing their own particular interests. These ‘rearguard actions’ are not 
in the interests of cancer patients. On that level, we still have some work to do.”
Bos ends on a telling anecdote. “A friend of mine recently told me that he had to go to hospital for 
an operation. As he had already been to another hospital some time previously and had had X-rays 
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taken there, he thought it would be practical to ask for these X-rays to be sent to the hospital where 
he was now being treated. It turned out that the hospital was unable to do this. He could pick the 
X-rays up himself, but it would cost him eleven euro. In the end he caught the train to the hospital 
and was eventually handed a CD with the X-rays on to take to the next hospital. When I heard this 
story I was quite saddened. As professionals working in the healthcare sector, we should be 
thoroughly ashamed of ourselves that such things happen!”
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Continuing professional 
education
Care for cancer patients requires professionals and care providers to have been basically educated 
in the medical, psychosocial and palliative aspects of cancer in terms of knowledge and skills.
Working group
However, to remain sufficiently competent, continuing education and 
experience is also required. Therefore, the Steering Committee of the Dutch 
NCCP considered this topic to be a major priority and installed a working 
group “Education”. Although the actions mentioned in the Dutch NCCP 
2005-2010 were much broader, the working group decided to focus on the 
education of medical professionals and nurses. The results and 
recommendations were published in the report “Deskundigheidsbevordering 
van artsen en verpleegkundigen in de oncologie” (Improvement of the 
professional expertise of physicians and nurses in oncology) in 2008.
Medical specialists
Some conclusions
 – Well-described oncological education, requirements and specific registration with regard to 
knowledge and skills in oncology are not available for all medical specialists
 – For those super specializations such as medical oncology, gynaecological oncology, surgical 
oncology, haematological oncology, head and neck oncology, urologic oncology, neurologic 
oncology, and paediatric oncology, general and sub competences have not always been 
well-formulated, neither harmonized.
Some recommendations
 – Can Meds is the tool medical specialists use to define the competencies needed; this tool 
should take oncology into account.
 – During medical specialists’ education, practical training focusing on diagnostics and 
treatments should be compulsory, under the supervision of a dedicated, registered specialist 
oncologist.
 – The national associations of scientific medical specialists should apply uniform re-registration 
requirements with regard to the recognized super specializations (e.g. annual hours for 
continuing education, participation in multidisciplinary teams).
Nurses and nurse practitioners
Some conclusions
 – The basic education for nurses (levels 4 and 5) is not sufficient for looking after cancer 
patients. To obtain the required level, an adequate education effort must be delivered.
Some recommendations 
 – In departments which mainly accommodate cancer patients, care should be provided by 
nurses who have received nationally recognized post-education in cancer.
 – This training programme needs to achieve the optimum relation between theory and practice 
and must be taught by competent teachers.
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 – Home care for cancer patients must be provided by home care nurses who have received 
supplementary education in cancer and palliative care (according to national criteria).
 – The basic education for nurses at intermediate (MBO) and higher (HBO) vocational level 
needs to incorporate basic knowledge and skills with regard to cancer as they will all come 
across cancer patients at some point. This should be added to the report “Gekwalificeerd 
voor de toekomst, kwalificatiestructuur en eindtermen voor verpleging en verzorging” 
(Qualified for the future. Qualification structure and final terms for nursing and care).16 
As the specialized education for nurse practitioners in cancer is quite recent, much more attention 
should be paid to the educators themselves, in terms of uniformity at national level and registration.
Cohesive plan for continuing professional development
Objectives
 – By 2005, details will be available concerning the institution (or websites) via which this 
overview can be accessed.
 – From 2006 onwards, there will be a central national overview of the annual plans (for 
continuing professional development in the area of oncological care) drawn up by the various 
parties involved in cancer care. The highest priority will be assigned to GPs, nursing home 
physicians, medical specialists, nurses and psychologists. After that, care providers, 
physiotherapists, dieticians, social workers, etc., will be involved.
Unfortunately, not enough manpower has been available to elaborate these objectives.
Education for other professionals and caregivers
 – Psychologists have developed a post-graduate training programme in oncology and 
registration. See http://www.nvpo.nl/index.php?option=content&pcontent=1&task=view&id=3
0&Itemid=58
 – A master class in palliative care for spiritual counsellors has been piloted and might be rolled 
out nationally. More attention will need to be paid to cancer.
 – For informal carers, local training programmes focused on cancer are sometimes available, 
but in general these programmes are more oriented towards palliative care.
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Research
In the Dutch NCCP 2005-2010, three main subjects were highlighted:
 – To improve researchers’ career prospects and the funding of cancer research from 2005 
onwards.
 – To enhance the opportunities for the implementation of scientific findings in the clinical 
situation.
 – To review the current legislation concerning the performance of clinical studies.
The development of improved treatments for cancer patients requires that basic scientific discoveries 
are translated into clinical applications. In spite of an increased interest in translational research in 
the Netherlands, multiple obstructions are preventing the smooth progression ‘from bench to 
bedside’. The Dutch NCCP and KWF acknowledge that cancer patients should benefit faster from 
scientific results and have prioritized translational research as their main topic. KWF has promoted 
translational research by:
 – increasing the budget for translational research projects;
 – increasing the budget for education and substantial expansion of the educational programme 
for scientists throughout their careers;
 – performing an inventory of the regulatory/legislative factors that are obstructing the 
performance of translational research (in collaboration with the Collaborative Healthcare 
Funds (Samenwerkende GezondheidsFondsen);
 – performing the Dutch NCCP project “Translational Research”.
The Dutch NCCP project “Translational Research” was initiated to help facilitate translational 
research, focusing on the steps involved in the development of therapeutic products up to phase I 
studies, in particular for those discoveries that are not rapidly taken up by the pharmaceutical 
industry. The development of these products requires an alternative route to ensure that they 
become available for clinical application. 
Objectives of the Dutch NCCP project “Translational Research”
 – To make an inventory of the numbers and types of scientific discoveries with potential clinical 
applications that were aborted during the development process (analyses of KWF research 
project files).
 – To identify factors that are currently slowing down the development process (interviews with 
scientists and organizations working in the field of translational cancer research). 
 – To intervene in four translational research projects that were already engaged in product 
development but had encountered obstructions which were halting progress, and to test 
whether possible solutions will indeed optimize the development process. 
 – To clear the confusion surrounding the regulations concerning the production of non-classic 
(cellular) therapeutics and the performance of clinical studies. 
What has been achieved?
 – The inventory shows that about 10% of the KWF research project files studied describe a 
product that is potentially clinically relevant. The majority of these research projects describe 
discoveries that can be classified as “tailor-made” (mainly immunological) therapeutics. 
 – Obstacles have been identified in the production of therapeutics and the availability of 
facilities, the regulations concerning the production of therapeutics and the performance of 
clinical studies, and it has been observed that there is the lack of translational research 
funding. 
 – The case studies show that relatively small interventions and investments can remove 
obstructions encountered on the route from bench to bedside:
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 – the desire and possibility to develop clinical products in an academic setting are 
present;
 – collaboration between research groups, the availability of knowledge, additional 
financial support and guidance for research projects are important factors in promoting 
the translational process; 
 – collaboration with research groups and pharmacists has resulted in the development 
of a model-IMPD (Investigational Medicinal Product Dossier) for non-classic (cellular) 
therapeutics, to assist scientists and pharmacists with regulatory issues. This model-
IMPD should contribute to uniformity and transparency regarding the information 
required to speed up the procedure for ethical review by the Central Committee on 
Research Involving Human Subjects (CCMO). 
 – The current infrastructure in the Netherlands is insufficiently equiped to offer these solutions 
on a structural basis. 
Former VIKC chairman Boi Jongejan
“Collaboration and continuity in cancer care remain essential”
The first step towards establishing a National Cancer Control 
Programme (Dutch NCCP) was taken just under ten years ago at the 
offices of the Association of Comprehensive Cancer Centres (VIKC). 
Boi Jongejan, then vice-chairman and secretary of the VIKC, and 
Renée Otter (then director of IKN and now chairwoman of the VIKC) 
came to the conclusion that collaboration within the broad spectrum of 
cancer care was both essential and inevitable. Jongejan looks back on 
the birth and early years of the Dutch NCCP with much satisfaction. He 
believes that the time has come for a fully mature National Cancer 
Control Programme. 
“Renée Otter and I were talking one day and noted that, while much was happening in the field of 
cancer care, there was little coordination. The Netherlands is a small country in which a large 
number of people and organizations do different things at different times. We saw opportunities for 
improvement. We wanted to introduce more structure and cohesion, to establish priorities and to 
bundle strengths where appropriate. Moreover, it is important to be able to present a joint front to 
the government, which not only determines policy but is a major source of funding. The same 
applies to communication with the general public. There are many organizations and professionals 
involved in cancer care. It would be good to present a clear, unified message through a single 
channel. We started to discuss our ideas for a national programme within our own organizations, 
where we received substantial support, and then went on to contact other organizations with a view 
to collaboration.”
Direction 
That it was the comprehensive cancer centres which initially proposed the Dutch NCCP was only 
logical, believes Jongejan, who would later go on to become chairman of the VIKC. “The VIKC exists 
to serve common interests and is primarily a support organization. We were therefore the ideal party 
to manage and direct the process. It took some time to get all five partners ‘on board’. Each had its 
own interests and priorities, but we focused on the things that we have in common.”
The Dutch Cancer Society (KWF) and the Dutch Federation of Cancer Patients’ Organizations (NFK) 
were the first to join the VIKC’s initiative. “The NFK was keen from the very outset,” recalls Jongejan. 
“They thought it an excellent idea. The KWF was a little more hesitant. As a large organization, it was 
used to doing things itself and being in control.” 
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The next partner to join was the Ministry of Health, Welfare and Sport (VWS). “Again, it took a little 
time to get the ministry involved. It had no previous experience in developing a broad approach to 
one specific disease. Cancer care was a first in this respect, but not the last. We now see a similar 
broad approach to diabetes, for example.”
Lobbying 
Jongejan, who in addition to his work for IKW and VIKC became chairman of the CBO (Institute for 
Health Care Improvement) and is currently director of the Oranje Kruis first-aid organization, clearly 
remembers the lobbying that was needed to win the ministry over. “I think the fact that the 
Netherlands was about to take up the presidency of the European Union played an important role. 
Because we had oriented ourselves internationally during the preparation stage, we knew that some 
other countries already had a national cancer control programme in place. We therefore suggested 
to the Minister of Health, Hans Hoogervorst, that it might not be appropriate for the country leading 
the entire EU to be without one. I think this was a decisive argument.” 
At the suggestion of the ministry, the Dutch Association of Healthcare Insurance Providers (ZN) 
became the fifth and final partner to join the initiative. “This was very quickly arranged following a 
meeting with its chairman, Hans Wiegel,” states Jongejan. He believes that the Dutch NCCP has 
made a huge difference. “There is now far more contact between the partners, and hence much 
better cooperation. In a multidisciplinary field such as oncology, this is a very important 
development. Moreover, we have succeeded in establishing certain priorities and in focusing on 
specific aspects of cancer care. Take translational research, for example, which is extremely 
important. Thanks to the Dutch NCCP, it has been possible to move scientific research out of the 
laboratory and into clinical practice more quickly. That is certainly a very welcome development.”
Patience 
Nevertheless, Boi Jongejan concedes that several aspects of the Dutch NCCP could be improved. 
“It will be a long and difficult process, not least because there are so many different people and 
organizations involved. There have to be meetings and consultations, which inevitably cause delays. 
That is frustrating, since one always prefers to see immediate results. It is often a question of 
patience. We have proposed a national screening programme for intestinal cancer, for example. 
Unfortunately, the Minister of Health, Ab Klink, has yet to approve the idea but this should not be 
reason for pessimism. After all, a ‘no’ today is not necessarily a ‘no’ forever. And if we look at 
smoking, we are still not where we want to be but at least the smoking ban in public places is a step 
in the right direction.”
Jongejan is most impressed by the Dutch NCCP spearheads of psychosocial and palliative care for 
cancer patients. “Sadly, we cannot prevent or cure every form of cancer. It is therefore extremely 
important that we continue to devote attention to those who are living with the disease. After all, we 
are talking about a very large group of people who wish to live out their remaining days in comfort 
and dignity. It’s all about the quality of life.”
Although Boi Jongejan no longer has any professional involvement with the Dutch NCCP, his 
personal interest and engagement remain strong. “I hope that the National Cancer Control 
Programme will be continued. Collaboration and continuity within cancer care remain essential. You 
cannot just ‘pull the plug’ and stop encouraging lifestyle changes or supporting translational 
research. I fervently hope that the Dutch NCCP has established a recognized position among the 
policy-makers. It should be seen as an essential component of our health care system. Cancer care 
can only benefit if the programme is given an even stronger position – and isn’t that what we all 
want?”
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Patient education and 
psychosocial care
Introduction
The disease cancer and its treatment not only give rise to physical symptoms, but often also to fear, 
depression, insecurity, impairment of self-esteem and a sense of lack of control. In addition, there 
are social consequences, such as loneliness or dependency. The confrontation with cancer may also 
lead to an existential crisis, which raises questions about what is meaningful and significant. And 
although work for most cancer patients is an important source of emotional support and financial 
independence, many cancer patients experience problems with their return to work. The burden 
cancer patients can experience on an emotional, physical, social, spiritual or practical level can be 
summarized by the term distress. 
In the Dutch NCCP, the mission of the working group “Psychosocial care and education” is stated as 
follows: “Patients and their relatives should be able to trust that the information, care and assistance 
they need to cope with the disease and its consequences are available to an optimal degree. (…) 
Psychosocial problems should be prevented and if they do occur, appropriate care must be 
provided.” (Dutch NCCP 2005-2010). To achieve these goals, a programme has been designed to 
ensure that every cancer patient in the Netherlands will receive good information and psychosocial 
care when this is needed.
In the field of education, many parties in the Netherlands are already actively involved. In particular, 
the role of KWF is prominent. Moreover, patient organizations like NFK and the Dutch Patient 
Consumer Federation (NPCF) play an active role. This has resulted in many initiatives to ensure 
adequate information provision to both individual patients and the general public. The increased use 
of the Internet warrants guidelines for reliable information sources. As there was no need to involve 
extra parties, these challenges in the Dutch NCCP were left to KWF and NFK.
With respect to psychosocial care there seems to be an ongoing loop (a vicious circle). Research 
has shown a discrepancy between cancer patients’ needs in terms of professional care and the care 
they actually receive (Report of the Health Council, (Gezondheidsraad), 2004). This is not surprising 
when we consider the elements of the vicious circle of psychosocial oncology referred to. 
Psychosocial problems in cancer patients are not systematically identified. As a result, those patients 
are often not provided with the care that is needed. As this care is provided only to a limited degree, 
it is difficult or impossible to investigate and measure the effectiveness of such care. As a result, not 
enough evidence is available to develop evidence-based care. Because the evidence base has not 
been sufficiently developed, it is not possible to develop evidence-based guidelines. This makes it 
difficult for insurers to determine what care should be financed. Because the funding does not come 
off the ground, is it is difficult for patients to obtain the care they need and as they are not 
systematically screened for psychosocial problems, their distress is not identified... And so on.  
 
To break this circle, significant progress should be made in all areas. To achieve this, close 
cooperation of all parties involved was needed. On this basis, working group “Integration of 
psychological care” (specially installed by the Dutch NCCP to focus on psychosocial oncology) 
formulated five targets which, when realized, should lead to the availability of the best possible care: 
screening, evidence, guidelines, education of professionals and funding of psychosocial care for all 
people with cancer in all stages of the disease. Later, monitoring of the goals was added as a target. 
Patient information
Objectives from the Dutch NCCP 
From 2007 onwards, patient information will meet the following criteria:
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 – Information will be provided in accordance with established ‘best practices’, as set out in a 
guideline. The requirements imposed by the Dutch law on medical treatment will also be 
included.
 – The topic of providing effective information to – and communication with – cancer patients will 
be incorporated into the basic educational programmes of all of the relevant care professions.
Current situation
A great deal of high-quality information for patients has become available, both on paper and 
through various websites, including the websites of KWF, the cancer patients’ organizations and 
their umbrella organization NFK, the IKCs and those of university medical centres. KWF, NFK and the 
IKCs are undertaking a project to coordinate, link and, where possible, combine all available 
information. The provision of information in accordance with established ‘best practices’ has been 
explored and needs further study. 
Psychosocial care
Objectives
By 2010:
 – A validated, cost-effective screening instrument capable of determining the need for 
specialized psychosocial assistance will be available and will have been widely introduced. 
This will enable all patients who need specialized psychosocial care to be detected and 
offered help.
 – Evidence for the effectiveness of psychosocial care will have been collected, reviewed and 
made available. 
 – Effective forms of psychosocial care will have been incorporated into the guidelines for 
oncological care.
 – Training in effective psychosocial care and communication will have been incorporated into 
the basic educational programmes for all of the relevant professions.
 – Effective psychosocial care and rehabilitation will have been incorporated into the standard 
health insurance package.
Current situation
The Dutch NCCP’s Steering Committee considered psychosocial care to be one of the main 
priorities of the Dutch NCCP 2005-2010. The working group “Integration of psychosocial care” was 
set up in order to elaborate all objectives. The Dutch Society for Psychosocial Oncology (NVPO) 
made the realization of the NCCP goals the main target of its policy for 2005-2010. The results 
achieved were due to the active participation of many members of NVPO.
Screening
 – A validated screening instrument has been developed by NVPO and the Comprehensive 
Cancer Centre North-East (IKNO) based on the Distress Thermometer. Its national 
implementation started in 2009, supported by the VIKC (www.lastmeter.nl). 
 – The guideline “Detection of the need for psychosocial care” was published on www.oncoline.
nl in June 2010, with the help of KWF.
 – A baseline inventory was made in 2009 to explore the current situation and the needs for the 
future.
 – A nationwide training programme for professionals of all hospitals (nurses, psychosocial 
professionals and staff) was developed and applied in 2009 and 2010 through the IKCs . 
Follow-up training is planned for 2010 and 2011.
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Evidence
 – A Cochrane review financed by KWF on the efficacy of professional psychosocial care one 
year after diagnosis has been conducted. More than 3000 publications (3380, published 
between 1990 and 2009) were studied and rated for their scientific quality based on 15 
criteria (e.g. randomized case control study design). Only 12 studies met the criteria. Results 
show that psychosocial care has a positive effect in diminishing distress in cancer patients. 
However, more research is needed to find out which intervention is most effective for which 
patient/problem. A national research agenda was recommended. Publication in the Cochrane 
library is expected in 2010. 
Psychosocial care in tumour-specific guidelines
 – NVPO and the IKCs agreed in 2006 to work on structural involvement of psychosocial experts 
in the development of evidence-based tumour-specific guidelines. However, in the recently 
adopted structure for guideline development, only the most urgent topics are addressed. 
Psychosocial care is rarely seen as urgent enough by medical experts to meet the criteria for 
inclusion in guidelines. 
 – To obtain an overview of the number and contents of tumour-specific guidelines with 
reference to patient information and psychosocial care, a search was conducted with financial 
support from KWF. Results show that in 50% of all tumour-specific clinical guidelines (www.
oncoline.nl) references to optimal patient information and communication and to detection of 
psychosocial needs and psychosocial care are included as part of the implementation of 
evidence-based oncological guidelines. 
 – To facilitate the implementation of psychosocial topics in the tumour-specific guidelines, 
recommendations for the incorporation of psychosocial topics have been made available. 
Development of quality of care criteria for guideline development and implementation of 
patient information, screening procedures and psychosocial care are being considered.
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Finance 
 – Structural financing of psychosocial care has been improved. Psychosocial oncological care 
has been included in the standard health insurance package. 
 – Psychosocial care in specialized centres is now available without costs being charged to the 
patient. However, structural financing and availability of psychosocial care in hospitals and 
rehabilitation are still poorly organized. 
 – To explore the specific problems and barriers, an invitational conference was organized on 
April 2nd 2009 and was attended by the most important stakeholders in the field: 25 
representatives of societies for cancer care professionals, care managers, insurance 
companies, the Ministry of Health, Welfare and Sport, and cancer patients’ organizations. The 
conference provided a clear insight into the bottlenecks and some possible solutions for the 
financing of psychosocial care. As a follow-up, the working group conducted further 
explorations with stakeholders of the health financing system and hospital management. The 
working group will publish a detailed report on the successes and challenges by November 
2010. 
Education of professionals in psychosocial oncology
 – Two specialized psycho-oncological education programmes have been developed and 
successfully implemented since 2007: one for medical psychologists in collaboration with the 
Central RINO group Utrecht (post-master education) and one for social workers in 
collaboration with HAN University of Applied Sciences.
 – Specialized psychosocial oncology centres (IPSO) and the ‘visitatie’ system on oncological 
care of IKCs have adopted these education programmes as the professional standards for 
psychologists and social workers working with cancer patients. 
 – A registration system has been developed by NVPO for professionals who have completed 
the programme; the registry is now available via the NVPO website.
 – A communication training programme in psychosocial oncology for medical specialists was 
developed in 2009. Two pilots were completed in 2009 and evaluated (positively) in 2010. 
Assurance
 – Standards for psychosocial support and screening have been included in the IKCs’ peer 
review system ‘visitatie’ on oncological care, as have standards on the educational level and 
the proportional formation of psychosocial staff/care providers.
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Experiences of health professionals with the Distress Thermometer
“Definitely an asset”
Teuna Esser and Jantien van der Sluis, nurse practitioners at 
Antonius Hospital in Sneek, think the Distress Thermometer 
(“lastmeter” in Dutch) is definitely an asset for cancer care, 
especially for the psychosocial aspects. “It is an excellent tool 
to discuss psychosocial problems. For both the patient and the 
doctor it is immediately clear how heavy the burden is and in 
what areas the patient is having difficulty. Based on the 
Distress Thermometer, direct action can be triggered,” said 
Teuna Esser. “The patient always has the lead in determining 
what will follow, which issues need addressing and what action 
will be taken.”
More acceptable
“A great additional advantage is that thanks to the list of topics 
one does not forget things,” continued Jantien van der Sluis. 
“And it is much easier for us to address certain problems one 
usually does not dare to ask about, such as finance or sexuality. These areas, like many other 
topics, are simply mentioned in the problem list of the Distress Thermometer.”
Additional resultant development
 – The guideline “Rehabilitation after cancer” has been developed and will be available as of 
December 2010 (www.oncoline.nl, www.herstelenbalans.nl).
Conclusion
With its commitment to improving psychosocial care in oncology in the Netherlands, Working Group 
“Integration of psychosocial care”, adopted a multi-focus approach. This approach was successful 
thanks to the collaboration within the Dutch NCCP. Psychosocial care is becoming a more integrated 
part of oncology care, but the opportunities for applying screening and psychosocial care are often 
not exploited, despite the recognized need for them by patients. Continued collaboration in a 
national programme is therefore important. 
The following points should receive attention as regards the near future. 
Screening 
 – Nationwide implementation of the guideline in hospitals.
 – Possible deployment of the guideline in first-line care.
 – Mapping of beneficial and harmful factors for deployment.
 – Adjustment of the guideline based on these experiences.
 – Monitoring of the extent to which this deployment is successful by recording in the national 
cancer registration system whether or not screening has been applied.
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Evidence
 – For further strengthening of evidence, the following has been proposed:
 – to establish a research agenda to which researchers can be invited. 
 – This requires that the constraints are formulated on the basis of quality and 
cooperation. 
 – These consultations can take place in collaboration with KWF and ZonMw (the 
Netherlands Organization for Health Research and Development) regarding 
opportunities for expansion of that research agenda.
 – Psychosocial care in all tumour-specific guidelines needs to be given further attention. Based 
on the inventory of directives made in 2010, the goals will be: 
 – to achieve both substantive and procedural agreement on the integration of 
psychosocial aspects in tumour-specific guidelines.
 – To formulate a ‘guideline for guidelines’ with respect to generic psychosocial 
components in tumour-specific guidelines.
 –  In addition: to develop and implement a guideline concerning the establishment of 
specialized high-quality psychosocial care.
Finance
 – For the accessibility of healthcare, its funding as part of the basic health insurance is a 
prerequisite. Bottlenecks that need to receive attention in the future are 1) 
 – The financing of psychologists and social workers in hospitals.
 – The financing of communicative interventions (screening), and 3) the distribution of 
psychosocial care outside the hospital across the country.
Professional education
 – A growing number of people will be confronted with the diagnosis of cancer during the next 
few decades. To meet the need for qualified care, recommendations on further expertise are: 
 – Setting quality standards for education and psychosocial care for each occupational 
group, both specialized psychosocial professionals and clinicians (doctors, nurses, 
and paramedics).
 – Establishing a registration system for specialized psychosocial professionals.
 – Training of a sufficient number of experts in psychosocial oncology to meet the needs 
of the growing number of cancer patients.
Assurance
 – Finally, to ensure true integration of psychosocial oncology, it is important that:
 – the indicators for good care are defined;
 – a standard of care is achieved in which the patients’ need for psychosocial care is met 
and integrated.
Support
The working group was able to achieve the results mentioned above with the help of many 
supporters. Financial support was received from:
 – Porticus Foundation, RCOAK and Ingeborg Douwes Foundation for a coordinator of the 
working group (2007-2010);
 – KWF for development of the screening guideline, for the exploration of psychosocial aspects 
in all tumour-specific guidelines and for the Cochrane review.
 – The IKCs supported the development and implementation of the screening guideline, the 
guideline “Rehabilitation after cancer” and the incorporation of standards for psychosocial 
care in their Hospital Inspection Standards (2010). 
 – The Ministry of Health, Welfare and Sport supported an invitational conference on the funding 
of psychosocial care (2009).
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Harm Jan Roelants, former member of the Dutch NCCP project team
“The bottom line is that the patient must benefit”
Harm Jan Roelants is the former director of the Dutch Federation of 
Cancer Patients’ Organizations. He is also one of the original architects of 
the National Cancer Control Programme 2005 – 2010 (Dutch NCCP). He 
and Henk Hummel (formerly of IKN and now with IKNO), formed the 
project team which provided the momentum for the entire programme. 
Roelants looks back on this period with much pleasure, but also has some 
critical comments about the way in which the Dutch NCCP was 
developed.
“We started work as a project team in 2003,” Roelants recalls. “Much of the necessary preparation 
had by then been undertaken by a steering group made up of the five partners: the Dutch Cancer 
Society (KWF), the Dutch Federation of Cancer Patients’ Organizations (NFK), the Association of 
Comprehensive Cancer Centres (VIKC), the Dutch Association of Healthcare Insurance Providers 
(ZN) and the Ministry of Health, Welfare and Sport (VWS). The early days were marked by many 
meetings and ongoing consultation, but little actual progress was made. It was therefore decided 
that a project team should be appointed to professionalize the process. That task fell to Henk 
Hummel and myself. We produced a project plan which set out exactly who was going to do what 
and when we were going to do it.”
Not a simple process
Although the five partners were relatively quick to make agreements regarding a broad-based, joint 
approach to cancer care, putting those agreements into practice proved rather more difficult. “It was 
not a simple process,” Roelants admits. “The partners had very different backgrounds and very 
different ideas. Of course there were also some differences in outlook, but that is good. All that really 
mattered was to get the programme up and running, and eventually we did so very successfully. We 
may have made a few mistakes along the way, but that is hardly surprising given the enormous 
scope of the Dutch NCCP project. We had no example to follow. A few other European countries, 
Denmark and the United Kingdom for example, had national cancer control programmes. We 
studied them to see what we could learn, but soon realized that we could not merely ‘transplant’ 
them into the Dutch situation. After all, every country has its own culture and its own way of 
structuring health services.”
It was in late 2004 that the National Cancer Control Programme was finally launched with the 
publication of a report. “The intention was that we would then make a start on the actual 
implementation, but little or nothing happened straight away,” Roelants recalls with some regret. “It 
was not until half 2005 that firm action was taken. Why the delay? Well, it was chiefly due to the way 
in which the project was organized. There was no shortage of plans and ambitions, but the partners 
could never seem to reach consensus.”
Roelants, who had devoted so much energy to setting up the programme, was unhappy with the 
way things were going. “In November 2004, Henk Hummel and I were thanked for our input and we 
thought that was the end of the matter. However, a few months later we were asked to return and 
pick up where we had left off. The programme was then brought under the wing of the Ministry of 
Health, which meant that funding and support were secure. The implementation of the plans could 
finally begin in 2006. In effect, we had lost twelve months.”
Essential 
Roelants remains a fervent supporter of the broad approach to cancer care in all its facets. “There 
are hundreds of organizations and tens of thousands of professionals who are involved in cancer 
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care to a greater or lesser degree. We are talking about huge numbers. Encouraging cooperation 
and coordination is therefore a condition sine qua non. For this reason alone, I would like to see a 
successor to the National Cancer Control Programme. That said, I also think that there are some 
aspects which should be modified.”
“In my view, the Dutch NCCP has been too ambitious. It gave rise to more expectations than could 
be met. At least a hundred different action points were formulated, but there were no firm plans for 
implementation for all of these. The necessary preconditions were not always put in place or the 
resources not made available. The parties who would be responsible for each initiative were named, 
but they included organizations other than the five original programme partners; in some cases 
those organizations failed to make any firm commitment that they would indeed do what had been 
asked of them.”
Roelants stresses that he continues to support the joint approach. “There are of course many 
projects that have been realized or at least put in motion. Topics which had previously enjoyed little 
or no attention have now been placed on the agenda. It’s just a shame that the successes are 
overshadowed by all the things which have not yet been accomplished.”
A successor to the Dutch NCCP
Asked whether the National Cancer Control Programme should be continued, Roelants does not 
have to think twice. “Yes, absolutely! But, as I have already said, a different approach is required. For 
example, at present there seems to be a clear demarcation between the programme and 
developments in the rest of the oncological field. I see that as a highly undesirable situation. For 
example, people say, ‘the Dutch NCCP achieved this, no one else – just us!’ It is entirely irrelevant 
who does what. What is important is that it gets done at all.”
Roelants believes that the key requirement is a well-functioning platform group in which all the main 
players within cancer care are represented. “That means that the health care professionals must also 
be involved. How do I see the role of the platform? It must set the agenda, identify the obstacles, 
lobby, monitor, communicate and educate. It must develop new initiatives and take responsibility for 
the actual implementation of essential activities. The aim should not be an all-embracing programme 
but rather a realistic approach geared to actual results. And the patient must notice the difference. 
After all, that’s what it’s all about. The bottom line is that the patient must benefit, in every sense of 
the word. Only when that is so, and when it is seen to be so, can you claim success.”
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Overall conclusions
This progress report on the developments relating to cancer control in the Netherlands in the period 
2005-2010 shows that there have been substantial changes in cancer control over the last five-year 
period. On the whole, survival rates have improved and mortality rates have decreased. Awareness 
of healthy living among the public at large has increased. The screening organizations have been 
reorganized and the degree of attention paid to screening programmes is high. Chain care, 
psychosocial care and palliative care have been supported by enormous incentives. For most of the 
various kinds of cancer, national guidelines are now available. Progress has been made in the 
monitoring of indicators for process, structure, organization and outcomes of cancer care. Focus on 
translational research facilitates the identification of further steps to be undertaken.
Within these developments, the Dutch NCCP has been the first comprehensive effort to optimize 
cancer control in the Netherlands. It has played an agenda-setting role and has set many activities in 
motion. Although many of the objectives of the NCCP have been met, a significant number of goals 
have yet not been achieved. As the incidence and prevalence of cancer in the Netherlands will 
increase enormously over the next ten years, a comprehensive cancer plan remains essential.
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 – N. Baselmans, VWS
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 – D. Habbema, Erasmus MC
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 – P.F. Roodbol, UMCG
 – D.T. Sleijfer, UMC
Working group “Integration of Psychosocial care”
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 – A.M. Van Dulmen, NIVEL
 – N. Golsteijn, V&VN
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 – M.E. Remie, NVPO, Stichting de Vruchtenburg
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Acronyms used
AMC-UVA   Amsterdam Medical Centre / University of Amsterdam
BVN   National Breast Cancer Patients Organization
CBS   Statistics Netherlands
CCMO    Central Committee on Research Involving Human Subjects
CVZ   Health Insurance Board
DBC   Diagnosis/Treatment Combination
ECL   European Cancer Leagues
ESR   European Standardized Rate
GBA   Local Authority’s Residents Registry 
GGD   Municipal Health Service
GP   General Practitioner
GR   Health Council of the Netherlands
HBO   Higher Vocational Education
HOVON   Haemato Oncology Foundation for Adults in the Netherlands
IGZ   Dutch Health Care Inspectorate 
IKC   Comprehensive Cancer Centre
IMPD   Investigational Medicinal Product Dossier
IPSO   Institute for Psychosocial Oncology
KNMG   Royal Dutch Medical Association
KWF    Dutch Cancer Society (‘KWF Kankerbestrijding’ in full)
LEBA    National Evaluation Team on Cervical Cancer Screening
LETB    National Evaluation Team on Breast Cancer Screening
LUMC   Leiden University Medical Centre
MBO   Intermediate Vocational Education
NABON  Dutch National Breast Cancer Consultation
NCCP   National Cancer Control Programme
NCR   Netherlands Cancer Registry
NIVEL   Netherlands Institute for Health Services Research
NFK   Dutch Federation of Cancer Patients’ Organizations
NHG   Dutch College of General Practitioners
NKI-AVL   Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital
NKR   Netherlands Cancer Registry of VIKC
NNGB   Dutch Standard for Healthy Physical Activity
NPCF    Federation of Patients and Consumer Organizations in the Netherlands 
NVCO   Dutch Society of Surgical Oncology
NVMO   Dutch Society of Medical Oncology
NVOV   Dutch Society of Oncology Nurses
NVPO   Dutch Psychosocial Oncology Society
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NVRO   Dutch Society of Radiology and Oncology
NVvO   Dutch Oncology Society 
PSA   Prostate-Specific Antigen
RCOAK  RCOAK charitable foundation
RIVM    National Institute for Public Health and the Environment
RPCF   Dutch Patient Consumer Federation
STIVORO  National Centre of Expertise for Smoking Prevention
TNO    Dutch Research Organization of Industry and Government
TNS NIPO  Market research company
UICC   Union for International Cancer Control
UMC   University Medical Centre
UMCG   University Medical Centre Groningen
VIKC   Association of Comprehensive Cancer Centres
VWS   Ministry of Health, Welfare and Sport
V&VN   Association of Nurses and Care Providers
WGBO  Medical Treatment Agreements Act
WHO   World Health Organization
WSR   World Standardized Rate
ZN    Dutch Association of Health and Social Care Insurance Companies
ZonMw   Netherlands Organization for Health Research and Development
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Relevant websites
www.cocancpg.eu
www.eurocanplus.org
www.ggd.nl
www.herstelenbalans.nl
www.hovon.nl
www.ikcnet.nl
www.ikcnet.nl/sib
www.ikcnet.nl/cijfers
www.kankerregistratie.nl
www.kwfkankerbestrijding.nl
www.lastmeter.nl
www.nfk.nl
www.nhg.nl
www.npknet.nl
www.npknet.nl/monitor
www.oncoline.nl
www.pallialine.nl
www.rivm.nl
www.stg.nl
www.stivoro.nl
www.zichtbarezorg.nl
www.zn.nl
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